Clinical trial NCT02781311
Conditions: Alopecia
Sponsor: Allergan
Start date: 2016-07-14; Completion date: 2018-05-22
Enrollment: 169 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).

Detailed description:

Arms: arm 1: Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks. arm 2: Two placebo tablets BID at 12-hour intervals for 24 weeks. arm 3: Finasteride 1 mg tablet, orally, once daily for 24 weeks.
Interventions: intervention 1: Setipiprant intervention 2: Placebo intervention 3: Finasteride
Intervention descriptions: intervention 1: Setipiprant tablets, orally, BID for 24 weeks. intervention 2: Placebo tablets, orally, BID for 24 weeks. intervention 3: Finasteride tablet, orally, once daily for 24 weeks.

Protocol documents:
Prot_000.pdf: 
NCT02781311 
 
Study ID: 1922-201-002  
 
Title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
PHASE 2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN 
MALES 
 
Protocol Amendment 1 Date: 17‐Feb‐2017 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
1 
GDD-TA-T-004 v2015.10 
 
Title Page 
ALLERGAN – CONFIDENTIAL 
The following contains confidential, proprietary information  
which is the property of Allergan 
 
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 
2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN MALES 
 
 
 
 
Protocol Number:   
1922-201-002 
Phase: 
2A 
Name of Investigational 
Product: 
Setipiprant Tablets 
Sponsor: 
 
Allergan (North America) 
2525 Dupont Drive 
Irvine, California USA 
92612 
+1-714-246-4500 
+1-800-347-4500 
 
 
Emergency Telephone 
Numbers: 
Refer to the Study Contacts Page 
Serious Adverse Event 
Reporting Fax Numbers: 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
2 
GDD-TA-T-004 v2015.10 
 
Allergan Medical Safety 
Physician 
Contact Information: 
 
 
Allergan Signatory: 
 
 
 
Refer to the final page of this protocol for electronic 
signature and date of approval. 
 
The following information can be found on FDA Form 1572 and/or study contacts page:  Name 
and contact information of Allergan study personnel and Emergency Telephone Numbers; name, 
address, and statement of qualifications of each investigator; name of each subinvestigator 
working under the supervision of the investigator; name and address of the research facilities to 
be used; name and address of each reviewing IRB; US 21 CFR 312.23 section 6(iii)b. 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
3 
GDD-TA-T-004 v2015.10 
 
INVESTIGATOR SIGNATURE PAGE 
INVESTIGATOR: 
 
 
 
 
I agree to: 
• Implement and conduct this study diligently and in strict compliance with the protocol, 
good clinical practices, and all applicable laws and regulations. 
• Maintain all information supplied by the sponsor in confidence and, when this information 
is submitted to an institutional review board (IRB), independent ethics committee (IEC) or 
another group, it will be submitted with a designation that the material is confidential. 
• Ensure that all persons assisting with the trial are adequately informed about the protocol, 
the investigational product(s), and their trial-related duties and functions. 
I have read this protocol in its entirety and I agree to all aspects. 
 
 
 
 
 
Investigator Printed Name 
 
Signature 
 
Date 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
4 
GDD-TA-T-004 v2015.10 
 
Table of Contents 
Table of Contents .............................................................................................................................4 
1. 
Background and Clinical Rationale ........................................................................................15 
2. 
Study Objectives and Clinical Hypotheses .............................................................................17 
2.1 
Study Objectives ...........................................................................................................17 
2.2 
Clinical Hypotheses ......................................................................................................17 
3. 
Study Design ...........................................................................................................................17 
 
 
3.2 
Data Monitoring Committee .........................................................................................18 
4. 
Study Population and Entry Criteria .......................................................................................18 
4.1 
Number of Subjects .......................................................................................................18 
4.2 
Study Population Characteristics ..................................................................................19 
4.3 
Inclusion Criteria ...........................................................................................................19 
4.4 
Exclusion Criteria..........................................................................................................20 
4.5 
Permissible and Prohibited Medications/Treatments ....................................................21 
4.5.1 
Permissible Medications/Treatments ...............................................................21 
4.5.2 
Prohibited Medications/Treatments .................................................................21 
4.5.3 
Special Activities .............................................................................................22 
5. 
Study Treatments ....................................................................................................................22 
5.1 
Study Treatments and Formulations ..............................................................................22 
5.2 
Control Treatments ........................................................................................................23 
5.3 
Methods for Masking/Blinding .....................................................................................23 
5.4 
Treatment Allocation Ratio and Stratification...............................................................23 
5.5 
Method for Assignment to Treatment Groups/Randomization .....................................23 
5.6 
Treatment Regimen and Dosing ....................................................................................24 
5.7 
Storage of Study Drugs .................................................................................................24 
5.8 
Preparation of Study Drugs ...........................................................................................24 
5.9 
Treatment Administration .............................................................................................25 
6. 
Response Measures and Summary of Data Collection Methods ............................................25 
6.1 
Efficacy Measures .........................................................................................................25 
6.1.1 
Primary Efficacy Measures ..............................................................................26 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
5 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
6.3 
Safety Measures ............................................................................................................31 
6.3.1 
Adverse Events ................................................................................................31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4 
Examination Procedures, Tests, Equipment, and Techniques .......................................34 
6.4.1 
Semipermanent Microdot Tattoo .....................................................................34 
6.4.2 
Global Photographs ..........................................................................................34 
6.4.3 
Macrophotography ...........................................................................................35 
6.5 
Summary of Methods of Data Collection .....................................................................35 
6.6 
Other Study Supplies .....................................................................................................36 
7. 
Statistical Procedures ..............................................................................................................37 
7.1 
Analysis Populations .....................................................................................................37 
7.2 
Collection and Derivation of Primary and Other Efficacy Assessments ......................37 
7.2.1 
Primary Efficacy Variables ..............................................................................39 
 
 
7.3 
Hypothesis and Methods of Analysis ............................................................................41 
7.3.1 
Primary Efficacy Analyses ...............................................................................41 
 
 
7.3.3 
Safety Analyses ................................................................................................43 
 
 
7.4 
Other Analyses ..............................................................................................................43 
 
 
7.6 
Interim Analyses............................................................................................................44 
8. 
Study Visit Schedule and Procedures .....................................................................................44 
8.1 
Subject Entry Procedures ..............................................................................................45 
8.1.1 
Overview of Entry Procedures .........................................................................45 
8.1.2 
Informed Consent and Subject Privacy............................................................45 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
6 
GDD-TA-T-004 v2015.10 
 
 
 
8.3 
Procedures for Final Study Entry ..................................................................................45 
8.4 
Instructions for the Subjects ..........................................................................................46 
8.5 
Unscheduled Visits ........................................................................................................46 
8.6 
Compliance With Protocol ............................................................................................46 
8.7 
Early Discontinuation of Subjects .................................................................................47 
8.8 
Withdrawal Criteria .......................................................................................................47 
8.9 
Study Termination .........................................................................................................47 
9. 
Adverse Events .......................................................................................................................47 
9.1 
Definitions .....................................................................................................................47 
9.1.1 
Adverse Event ..................................................................................................47 
9.1.2 
Serious Adverse Event .....................................................................................48 
9.1.3 
Severity ............................................................................................................49 
9.1.4 
Relationship to Study Drug or Study Procedure ..............................................49 
9.2 
Procedures for Reporting Adverse Events ....................................................................49 
 
 
 
 
10.  Administrative Items ..............................................................................................................50 
10.1  Protection of Human Subjects .......................................................................................51 
10.1.1  Compliance with Informed Consent Regulations (US 21 CFR Part 50) and 
Relevant Country Regulations .........................................................................51 
10.1.2  Compliance With IRB or IEC Regulations ......................................................51 
10.1.3  Compliance With Good Clinical Practice ........................................................51 
10.1.4  Compliance With Electronic Records; Electronic Signatures Regulations 
(US 21CFR Part 11) .........................................................................................51 
10.2  Changes to the Protocol ................................................................................................51 
10.3  Subject Confidentiality .................................................................................................51 
10.3.1  Subject Privacy ................................................................................................52 
10.4  Documentation ..............................................................................................................52 
10.4.1  Source Documents ...........................................................................................52 
10.4.2  Case Report Form Completion ........................................................................53 
10.4.3  Study Summary ................................................................................................54 
10.4.4  Retention of Documentation ............................................................................54 
10.5  Labeling, Packaging, and Return or Disposal of Study drugs/Treatments ...................54 
10.5.1  Labeling/Packaging ..........................................................................................54 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
7 
GDD-TA-T-004 v2015.10 
 
10.5.2  Clinical Supply Inventory ................................................................................55 
10.5.3  Return or Disposal of Study Drugs and/or Supplies ........................................55 
10.6  Monitoring by the Sponsor ...........................................................................................55 
 
10.8  Publications ...................................................................................................................56 
10.9  Coordinating Investigator .............................................................................................56 
11.  References ...............................................................................................................................57 
12.  Attachments ............................................................................................................................59 
12.1  Examination Procedures, Tests, Equipment, and Techniques .......................................59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12.2  Safety Measures ............................................................................................................91 
12.3  Glossary of Abbreviations .............................................................................................93 
12.4  Protocol Amendment Summary ....................................................................................95 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
8 
GDD-TA-T-004 v2015.10 
 
Protocol Summary 
 
Study Compound: Setipiprant, a tetrahydropyridoindole derivative 
Phase: 2a 
Study Objectives  
1) To evaluate the safety, tolerability, and efficacy of oral administration of setipiprant tablets 1000 mg twice daily 
(BID) relative to placebo in males with androgenetic alopecia (AGA) who are 18 to 49 years old and in generally 
good health.  
 
 
Clinical Hypotheses  
• Setipiprant tablets 1000 mg BID have an acceptable safety profile following oral administration for 24 weeks. 
• Setipiprant tablets 1000 mg BID are more effective than placebo in increasing hair growth, as measured by the 
change from baseline in target area hair count (TAHC) in terminal hairs/cm2 using digital image analysis at 
24 weeks after oral administration. 
• Setipiprant tablets 1000 mg BID are more effective than placebo in increasing scalp hair growth, as measured by 
the distribution of the Subject Self-Assessment (SSA) scores using a 7-point scale at 24 weeks after oral 
administration. 
Study Design  
Structure: Multicenter, randomized, double-blind, placebo-controlled study designed to determine the effect of 
treatment with setipiprant tablets 1000 mg BID on scalp hair growth as assessed by objective (ie, imaging-based) 
and subjective (ie, 
 subject-reported) measures.  
Duration: Approximately 32 weeks (enrollment through exit) 
Study Treatment Group: Setipiprant tablets 1000 mg BID 
Control: Placebo BID  
Dosage/Dose Regimen: Setipiprant tablets 1000 mg BID or placebo tablets BID  
Enrollment/Stratification:  
•
 
  
 
 subjects will be randomized in a1:1 ratio to receive setipiprant tablets 1000 mg BID or 
placebo BID, and stratified by baseline age 18 to 34 and 35 to 49 years. 
 
 
Study Population Characteristics 
Number of Subjects: Approximately 187 will be enrolled in up to 20 US sites 
Condition/Disease: Androgenetic alopecia with vertex patterns IIIv, IV, or V as assessed with the Norwood-
Hamilton Hair Loss Scale (NHS) 
Key Inclusion Criteria:  
• Male subjects in generally good health, aged 18 to 49 years (inclusive) 
• Androgenetic alopecia with vertex patterns IIIv, IV, or V on the NHS 
• 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
9 
GDD-TA-T-004 v2015.10 
 
Key Exclusion Criteria:   
• History or evidence of hair loss for reasons other than AGA  
• Scarring of the scalp or any condition or disease of the scalp, hair, or hair shaft (
 
 
 
Response Measures 
Coprimary Efficacy Measures: change from baseline in TAHC of terminal hairs/cm2 as measured using digital 
image analysis and subject self-assessment of change from baseline in hair growth as measured by the distribution of 
SSA scores 
 
 
 
 
 
 
 
  
 
  
 
 
General Statistical Methods and Types of Analyses  
Two analysis populations are defined: modified intent-to-treat (mITT) and safety. The mITT population, consisting 
of all randomized subjects who have a baseline and at least 1 postbaseline primary efficacy measurement, will be 
used for analyses of efficacy data based on the randomized treatment group. The safety population, consisting of all 
treated subjects, will be used for analyses of all safety data based on the actual treatment received. Hypothesis 
testing will be 2-tailed with a significance level of 0.05. Pairwise comparisons of setipiprant tablets 1000 mg BID 
versus placebo will be made. The finasteride subjects enrolled prior to protocol Amendment 1 will be summarized 
alone and will not be included in the analysis models to compare with the other treatment groups. For all efficacy 
analyses, no adjustment of significance levels will be made for multiplicity of treatment comparisons. 
Efficacy Analyses: The 2 coprimary efficacy variables are: 1) change from baseline in TAHC of terminal hairs/cm2 
within a 1 cm2 circular area on the left side at Week 24; and 2) SSA of change from baseline in hair growth at 
Week 24. The 2 coprimary efficacy variables will be analyzed using an analysis of covariance (ANCOVA) model 
with treatment (excluding the finasteride group as described above) as a fixed effect and age and baseline value as 
covariates (if applicable). The treatment difference for setipiprant tablets 1000 mg BID versus placebo BID will be 
constructed based on this ANCOVA model, along with the 2-sided p-value. 
 
 
 
 
 
 
 
 
. Missing data of TAHC and SSA will be imputed up to Week 24 using last observation carried forward 
(LOCF). 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
10 
GDD-TA-T-004 v2015.10 
 
Safety Analyses: All safety analyses will be performed on the safety population. Adverse events will be coded from 
the verbatim text into preferred term (PT) and primary system organ class (SOC) by using the Medical Dictionary 
for Regulatory Activities. The number and percent of subjects reporting treatment-emergent AEs at least once 
regardless of causality will be tabulated. Similarly, treatment-related AEs will be tabulated. The tables will be 
generated by primary PT and SOC as well as by severity. Safety data will be summarized by frequency distributions 
or descriptive statistics and described in the detailed analysis plan. 
 
 
 
  
Sample Size Calculation: The study plans to enroll approximately 152 subjects in the setipiprant 1000 mg BID 
(n = 80) and placebo BID (n = 72) groups. Of the 152 subjects to be enrolled, 12 subjects will be randomized to the 
 The remaining 140 subjects will be randomized 
 at 1:1 ratio and stratified by baseline age group (18 to 34 and 35 to 49 years). 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
11 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
12 
GDD-TA-T-004 v2015.10 
 


 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
13 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
14 
GDD-TA-T-004 v2015.10 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
15 
GDD-TA-T-004 v2015.10 
 
1. 
Background and Clinical Rationale  
Androgenetic alopecia (AGA) is the most prevalent cause of hair loss in both men and women 
(Sinclair, 1998; Severi et al, 2003; Stough et al, 2005). It has been estimated that across the 
lifespan of a person, AGA may affect approximately 70% of men and 40% of women 
(McElwee and Shapiro, 2012). For many among those affected by AGA, research suggests that 
negative psychological effects can occur as a result of the condition (Tabolli et al, 2013). As 
such, the field of dermatology has had a high interest in developing effective treatments for 
AGA. Currently available treatment options provide some clinical benefit in treating AGA. 
However, monotherapy with these agents provide either limited efficacy or have been associated 
with unfavorable side effect profiles (Falto-Aizpurua et al, 2014; DiLoreto et al, 2014; 
Altomare et al, 2002; Caruso et al, 2015). Finasteride is approved only for male patients. Thus, 
innovative treatment approaches are needed in the search for agents that provide improved 
efficacy and tolerability for treatment of subjects with AGA.  
Research suggests a role of the prostaglandin pathway in the inhibition of hair growth and is 
based on the following findings: a) the level of prostaglandin D2 (PGD2) in the balding scalp of 
men with AGA is significantly elevated when compared with the level in nonbalding scalp in the 
same individual; b) PGD2 blocks the growth of human hair follicle mini organ in ex vivo 
cultures; and c) topical application of PGD2 to the back of wild type mice prevents hair growth 
(Garza et al, 2012). The enzyme responsible for synthesizing the agonist to PGD2, 
prostaglandin-D2 synthase (PTGDS), is expressed in nonpermanent keratinocytes of the human 
hair follicle (Garza et al, 2012). Mice genetically engineered to overexpress the mouse PTGDS 
homolog (ptgs2) are unable to grow hair suggesting that increased PGD2 prevents hair growth 
(Garza et al, 2012). The G-protein-coupled receptor for PGD2 is a chemoattractant receptor-
homologous molecule expressed on T helper 2 cells (CRTH2). CRTH2 is expressed in the 
dermal papilla and outer root sheath cells of human hair follicles (Colombe et al, 2008). In 
CRTH2 knockout mice, hair growth is insensitive to topical PGD2 application, thereby 
suggesting that the growth inhibitory effect is mediated by the CRTH2 receptor (Garza et al, 
2012). The growth inhibitory effect of PGD2 can be abolished in human hair follicle mini organ 
culture with CRTH2 antagonists (Cotsarelis et al, 2015a). 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
16 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Setipiprant effectively prevents PGD2-induced hair growth inhibition in human hair follicle mini 
organ cultures (Cotsarelis et al, 2015b). Thus, the purposes of this study include the use of the 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
17 
GDD-TA-T-004 v2015.10 
 
study data to develop a better understanding of whether setipiprant tablets are capable of treating 
AGA in males and to assist in the design of future clinical trials.   
2. 
Study Objectives and Clinical Hypotheses  
2.1 
Study Objectives 
The study objectives are:  
1) To evaluate the safety, tolerability, and efficacy of oral administration of setipiprant 
tablets 1000 mg BID relative to placebo in males with AGA who are 18 to 49 years old and in 
generally good health. 
. 
2.2 
Clinical Hypotheses 
• Setipiprant tablets 1000 mg BID have an acceptable safety profile following oral 
administration for 24 weeks. 
• Setipiprant tablets 1000 mg BID are more effective than placebo in increasing hair growth, as 
measured by the change from baseline in target area hair count (TAHC) of terminal hairs 
(1 cm2 circular area) using digital image analysis at 24 weeks after oral administration. 
• Setipiprant tablets 1000 mg BID are more effective than placebo in increasing scalp hair 
growth, as measured by the distribution of Subject Self-Assessment (SSA) scores using a 
7-point scale at 24 weeks after oral administration. 
3. 
Study Design 
This is a multicenter, randomized, double-blind, placebo-controlled study with an active 
comparator group designed to determine the effect of treatment with setipiprant tablets 1000 mg 
BID on scalp hair growth as assessed by objective (ie, imaging-based) and subjective (ie, 
investigator- and subject-reported) measures.  
All investigators, site staff, and subjects will be blinded to whether subjects receive setipiprant or 
matching placebo during the study. 
Subjects must complete all screening and baseline procedures and meet all eligibility 
requirements to qualify for enrollment and randomization on Day 1 when they will be randomly 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
18 
GDD-TA-T-004 v2015.10 
 
assigned to 1 of 2 treatment groups (setipiprant or placebo). All subjects will self-administer the 
assigned study drug over a 24 week period to evaluate the safety and effects on hair growth. 
After randomization, subjects will return to the research facility at Weeks 
,
 24 for 
protocol-defined efficacy and/or safety assessments and procedures, confirmation of compliance 
with study drug usage, and new study drug dispensation (except for Week 24). A follow-up visit 
will occur at Week 32 (ie, 8 weeks posttreatment) or the early exit visit for protocol-defined 
efficacy and safety evaluations and procedures.  
Safety and efficacy assessments and study procedures are outlined in the Study Design and 
Schedule of Assessments (Table 1). The SSA will be evaluated at Weeks 
 24, and 32 (or 
early exit visit) using the subject’s paired and randomly blinded screening (the screening 
photograph is defined as the subject’s baseline) and postbaseline photographs, and at Weeks 24 
and 32 (or early exit visit) using the subject’s paired, unblinded screening and postbaseline 
photographs. 
 
 
 
 
 
 
 
 
 
  
3.2 
Data Monitoring Committee 
Although a data monitoring committee will not be established for this study, the medical safety 
physician (MSP) will perform an ongoing review of safety data in a blinded manner throughout 
the 24-week treatment period.  
4. 
Study Population and Entry Criteria 
4.1 
Number of Subjects  
Approximately 152 subjects will be randomized to 1 of 2 treatment groups (setipiprant 1000 mg 
BID, n = 80; placebo BID, n = 72) at up to 20 study centers in the US.  


Approval Date: 17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
19 
GDD-TA-T-004 v2015.10
 
  
 Approximately 140 subjects will be randomized in a 1:1 ratio to 
 
group (setipiprant 1000 mg BID, placebo BID), and stratified by baseline age, 18 to 34 and 35 to 
49 years.). 
 
4.2 
Study Population Characteristics 
Males, aged 18 to 49 years (inclusive) and in generally good health, with AGA vertex patterns 
IIIv, IV, or V on the Norwood-Hamilton Hair Loss Scale (NHS; Norwood, 1975; A12.1.2), will 
be included in this study. Males aged 18 to 41 years were also assigned to finasteride prior to 
protocol Amendment 1. 
4.3 
Inclusion Criteria 
The following are requirements for entry into the study:  
1. Written informed consent
2. Written documentation in accordance with the relevant country and local privacy
requirements, where applicable (eg, Written Authorization for Use and Release of Health and
Research Study Information)
3. Males, aged 18 to 49 years (inclusive) and in generally good health
4. Androgenetic alopecia with vertex patterns IIIv, IV, or V on the NHS
6. Agreement from the subject to maintain current hair care regimen 
 and refrain from hair weaving, hair
colorants or dyes, and nonstudy hair growth products for the duration of the study


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
20 
GDD-TA-T-004 v2015.10 
 
4.4 
Exclusion Criteria 
The following are criteria for exclusion from participating in the study: 
1. History or evidence of hair loss for reasons other than AGA 
 
 
2. Scarring of the scalp or any condition or disease of the scalp, hair, or hair shaft 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Hair-weaving procedure within 6 months prior to baseline 
6. Use of hair colorants or dyes within 6 months prior to baseline or presence of residual traces 
of colorants in the hair at baseline   
7. Patients who have a clinically significant finding or condition (eg, patients with malignancies, 
HIV, or other immunocompromising conditions), any uncontrolled systemic disease, or are in 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
21 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
4.5 
Permissible and Prohibited Medications/Treatments 
4.5.1 
Permissible Medications/Treatments 
Therapy considered necessary for the subject's welfare may be given at the discretion of the 
investigator. If the permissibility of a specific medication/treatment is in question, please contact 
the sponsor. 
4.5.2 
Prohibited Medications/Treatments 
The decision to administer a prohibited medication/treatment is done with the safety of the 
subject as the primary consideration. When possible, the sponsor should be notified before the 
prohibited medication/treatment is administered. 
 
 
: 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
22 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The investigator will record details of all concomitant medication use and concurrent procedures.  
4.5.3 
Special Activities 
Subjects must refrain from changing their hair style and hair color for the duration of the study. 
Excessive use of hair sprays or hair dryers should be avoided.  
5. 
Study Treatments  
5.1 
Study Treatments and Formulations 
From randomization 
, the study drug will be dispensed for oral dosing to 
subjects in tablet form as follows:  
Setipiprant: Two setipiprant tablets at 500 mg BID  
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
23 
GDD-TA-T-004 v2015.10 
 
5.2 
Control Treatments 
Placebo: Two placebo tablets BID 
 
 
 
5.3 
Methods for Masking/Blinding 
Evaluation of the setipiprant and placebo treatment groups will be conducted in a double-blind 
manner so that neither the site personnel nor the subject is aware of which treatment is 
administered. Both treatments will be identical in appearance 
Except when it is essential for the medical management of the subject or bioanalytical reasons 
(ie, to enable bioanalysis of samples only from subjects who receive active treatment), 
unblinding the treatment assignment will be considered a protocol deviation. Instructions for 
access to emergency treatment allocation information will be available by secured access to the 
interactive web response system (IWRS). If possible, the investigator should contact the sponsor 
before unblinding any subject’s treatment assignment. In the event that this is not possible, the 
sponsor must be notified within 24 hours after the unblinding event. After unblinding, the subject 
will be discontinued from study drug treatment and will return for a final follow-up (ie, Week 32 
or early exit visit).  
5.4 
Treatment Allocation Ratio and Stratification 
 
. The 140 subjects 
 will be randomized to 
setipiprant and placebo at a 1:1 ratio to be stratified by baseline age group (18 to 34 and 35 to 
49 years). 
5.5 
Method for Assignment to Treatment Groups/Randomization 
At screening, each subject who provides informed consent will be assigned a subject number that 
will serve as the subject identification number on all study documents. 
At the time of randomization (ie, Day 1 [baseline] visit), eligible subjects will be randomly 
assigned. 
 
 subjects will be 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
24 
GDD-TA-T-004 v2015.10 
 
randomized in a 1:1 ratio to receive setipiprant tablets 1000 mg BID or placebo BID stratified by 
baseline age group (18 to 34 and 35 to 49 years).  
An automated IWRS will be used to manage the randomization and treatment assignment based 
on a randomization scheme prepared by Allergan Biostatistics. 
Study medication will be labeled with medication kit numbers. The IWRS system will provide 
the site with the specific medication kit number(s) for each randomized subject at the time of 
randomization. Sites will dispense study drugs according to the IWRS instructions. Sites will 
also log into the IWRS at subsequent visits to obtain a study drug kit number(s) for study drugs 
as required. Sites will receive the IWRS confirmation notifications for each transaction. All 
notifications are to be maintained with the study source documents. 
5.6 
Treatment Regimen and Dosing 
Each subject will self-administer their respective treatment for 24 weeks as follows: 
Setipiprant and placebo regimen: Subjects will self-administer the assigned study drug (2 tablets 
of setipiprant 500 mg or placebo) orally with water at approximately 12-hour intervals and at 
least 1 hour before or 2 hours after eating, eg, 1 hour before breakfast in the morning and at least 
2 hours after dinner. Subjects assigned to the finasteride group prior to protocol Amendment 1 
will continue treatment until they complete the study. 
5.7 
Storage of Study Drugs 
Study drugs must be stored in a secure area and dispensed only to subjects entered into the 
clinical study, at no cost to the subject, in accordance with the conditions specified in the 
protocol. 
Sites should store study drugs at controlled room temperature between 
 
. Sites will monitor the temperature of the storage area and report any temperature 
excursions as described in the study reference manual or contact the sponsor or its designee for 
further instructions. 
Subjects will be instructed on the proper storage of study drugs and to keep it out of the reach of 
children. All study drug packages will have child-resistant features. 
5.8 
Preparation of Study Drugs 
Not applicable 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
25 
GDD-TA-T-004 v2015.10 
 
5.9 
Treatment Administration  
From randomization through Week 24, subjects will self-administer 2 setipiprant 500 mg tablets 
BID or 2 placebo tablets BID.  
Setipiprant and placebo packaging and dosing: Setipiprant and placebo will be packaged in 
blister packs containing the coated tablets and combined into a weekly wallet. Each weekly 
wallet of setipiprant or placebo will contain a total of 14 doses (ie, a week’s worth of BID 
dosing).  
 
 
 
 
  
The investigator will dispense an appropriate number of weekly wallets for the time interval until 
the subject’s next clinic visit. Because this is a double-blind study, labeling of the subject 
treatment kit will not show the treatment allocation. All other information required by regulation 
will appear on each treatment kit.  
6. 
Response Measures and Summary of Data Collection Methods 
6.1 
Efficacy Measures   
Multiple products have been studied and approved for the treatment of AGA in recent years and 
have employed objective hair counts, cumulative width, and darkness estimates via 
macrophotography; independent investigator, subject, and expert panel comparative evaluations 
of pre- and posttreatment global photographs; and multi-item subject questionnaires. Similar 
procedures, assessments, and questionnaires will be utilized in this study. 
To avoid introducing response bias during the study, the subject must complete the self-
assessments independently and prior to evaluation by the investigator (ie, the subject-reported 
assessments must be completed before the investigator-reported assessments). The investigator’s 
current or previous evaluations must not be disclosed to the subject nor must the subject be 
reminded of any of his previous responses provided during any assessment. For unbiased 
investigator assessments, subject responses must also not be disclosed to the evaluating 
investigator.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
26 
GDD-TA-T-004 v2015.10 
 
All staff and subjects will be blinded to whether subjects receive setipiprant or matching placebo 
during the study. Staff must administer all subject assessments and not divulge the results of 
these assessments to the evaluating investigator. The sponsor will provide guidance regarding 
what study personnel may say and must not say to a subject regarding any perceived 
improvement to avoid influencing responses on the subject-reported assessments. When possible, 
the evaluator(s) performing the 
 at an individual study 
center should perform all evaluations for a given subject, and if possible, all subjects throughout 
the study. In the rare event that there is a change in the assigned evaluator for a given subject, the 
reason for change must be documented. If it is not possible to use the same evaluator to follow a 
given subject, the sponsor recommends that evaluations between the primary and subsequent 
evaluator overlap (ie, both evaluators should examine the subject together and discuss findings 
without the subject present) for at least 1 visit; this should be documented. 
6.1.1 
Primary Efficacy Measures 
6.1.1.1 
Target Area Hair Count (Within a 1 cm2 Circular Area) 
One of the coprimary efficacy measures will be the subjects’ TAHC as measured in terminal 
hairs (1 cm2 circular area on the left side) using digital image analysis (A12.1.4). 
 
 
 
 
 
  
The total number of terminal hairs (hair width ≥ 30 µm) will be calculated from 
macrophotographs. The target area used to count TAHC will be a 1 cm2 circular area of clipped 
hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area 
of the scalp and centered with a semipermanent microdot tattoo to ensure the same target area is 
reproduced at each visit. 
6.1.1.2 
Subject Self-Assessment 
The SSA (A12.1.7) is a coprimary measure that consists of a single item that assesses each 
subject’s perception of change in scalp hair growth. The subject uses a standardized global 
photograph of his scalp taken at the screening visit (the screening photograph is defined as the 
subject’s baseline) presented side by side with a standardized global photograph taken at the 
postbaseline visit to give a comparative score. The photographs are presented in a blinded and 
randomized manner, and response options are on a 7-point ordinal scale. Refer to the imaging 
vendor manual for the methodology for obtaining global photographs.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
27 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
28 
GDD-TA-T-004 v2015.10 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
29 
GDD-TA-T-004 v2015.10 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
30 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
31 
GDD-TA-T-004 v2015.10 
 
6.3 
Safety Measures 
Safety measures will include AEs, vital sign measurements (pulse rate, blood pressure, and 
respiratory rate), physical examinations, 12-lead ECG, and laboratory tests (biochemistry, 
hematology, and urinalysis).  
6.3.1 
Adverse Events 
The investigator will question the subject to ascertain whether any AEs were experienced since 
the previous visit. All pertinent information regarding AEs (ie, date of onset and stop, duration, 
outcome, severity, relationship to study drug, action or required treatment) will be obtained and 
recorded in the source documents and appropriately transcribed on the electronic case report 
form (eCRF) page. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
32 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
6.3.6 
Nonscalp Hair Growth 
Starting at Week 8, subjects will be queried at each visit whether they have noticed any hair 
growth in nonscalp areas (yes/no) and this response will be captured in the eCRF. If judged by 
the investigator as clinically significant, nonscalp hair growth may be reported as an AE.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
33 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
34 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
  
6.4 
Examination Procedures, Tests, Equipment, and Techniques 
All study photographs will be standardized for lighting, camera angle, and position of the 
subject’s head 
 Images will be uploaded to a secure website 
made available by the photography vendor, 
 via flash drive or internet 
transfer. Detailed instructions for all aspects of the photography procedures will be supplied 
separately 
. 
6.4.1 
Semipermanent Microdot Tattoo 
For standardized photography, during the Day 1 (baseline) visit, subjects will receive two 1-mm 
semipermanent microdot tattoos 
 
 
 
 
 
 
. As the dots begins to fade or are at risk of fading before the next scheduled 
visit, they may be refreshed in the exact same locations.  
6.4.2 
Global Photographs  
Two standardized global photographs (vertex target area and frontal area) will be taken at 
screening (the screening photograph is defined as the subject’s baseline) and at Weeks 
, 24, 
and 32 (or early exit visit). At Weeks 
, 24, and 32 (or early exit visit), after refreshing the 
semipermanent microdot tattoo (if necessary) and parting and combing the hair radially away 
from the part, standardized global photographs of the subject’s vertex target area will be 
presented in pairs (ie, 1 photograph taken at screening and the other photograph taken at a given 
treatment week 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
35 
GDD-TA-T-004 v2015.10 
 
 
 
 
  
6.4.3 
Macrophotography 
Macrophotography will be performed at Day 1 (baseline) and Weeks 
, 24, and 32 (or early 
exit visit). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.5 
Summary of Methods of Data Collection 
This study will use eCRFs using remote electronic data capture through a qualified third party 
vendor. The data will be entered on the eCRFs in a timely manner on an ongoing basis. The 
investigator is responsible for ensuring that data are properly recorded on each subject’s eCRFs 
and related documents. An investigator who has signed the protocol signature page should 
personally electronically sign for the eCRFs (as indicated in the eCRFs) to ensure that the 
observations and findings are recorded on the eCRFs correctly and completely. A certified 
electronic copy of the eCRFs including data corrections will be provided to the site for archiving 
at the end of the study. 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
36 
GDD-TA-T-004 v2015.10 
 
. 
 
 
 
 
 
  
 
  
6.6 
Other Study Supplies 
The following will be provided by the sponsor: 
• Modified NHS 
The following will be provided by the investigator: 
 
 
 
 
  
 
 
 
 
• Sterile pads 
• Gloves 
• Sphygmomanometer 
• Equipment to measure height and body weight 
• Equipment (stethoscope, otoscope, etc) to conduct physical examinations 
• Internet connection (high-speed connection for eCRF completion and digital image uploads) 
The following will be provided by the central laboratory: 
• All supplies needed for 
 
• Shipping materials for shipment 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
37 
GDD-TA-T-004 v2015.10 
 
The following will be supplied by 
.: 
• Standardized photography equipment, including the instruction manual 
• Equipment for tattoo and shaving 
 
•
 
7. 
Statistical Procedures 
7.1 
Analysis Populations 
Two analysis populations are defined: modified intent-to-treat (mITT) and safety. The mITT 
population, consisting of all randomized subjects who have a baseline and at least 1 postbaseline 
measurement for 1 of the coprimary efficacy measures, will be used for analyses of efficacy data 
based on the randomized treatment group. The safety population, consisting of all subjects who 
receive at least 1 dose of study drug (ie, all treated subjects), will be used for analyses of all 
safety data based on the actual treatment received. All subjects who ingest at least 1 dose of 
study drug will be included in the safety analysis population included in the summaries of all 
safety and demographic data. All efficacy variables will be summarized and analyzed using the 
mITT population. 
7.2 
Collection and Derivation of Primary and Other Efficacy 
Assessments 
The coprimary efficacy variables will be based on the following 2 measures: TAHC within a 
1 cm2 circular area on the left side of the scalp and SSA. 
• The TAHC is a standardized objective quantification of each subject’s number of terminal 
hairs (hair width ≥ 30 µm) within a 1 cm2 target circular area on the left side located at the 
anterior leading edge of the vertex thinning area of the scalp using digital image analysis. 
• The SSA score is the subject’s assessment of change of hair growth, scored on a 7-point scale 
(−3 = greatly decreased, −2 = moderately decreased, −1 = slightly decreased, 0 = remained the 
same, +1 = slightly increased, +2 = moderately increased, and +3 = greatly increased). The 
analyses of the SSA from the blinded photograph assessments will be based on the actual 
change from the screening photographs (ie, if the postbaseline photograph is used as Photo A, 
the assessment score will be reversed for analyses).  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
38 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
39 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.1 
Primary Efficacy Variables  
The 2 coprimary efficacy variables are based on the measurements of TAHC and SSA (blinded).  
• Change from baseline in TAHC within a 1 cm2 target circular area on the left side located at 
the anterior leading edge of the vertex thinning area of the scalp at Week 24 
• Subject Self-Assessment of change from baseline in hair growth as viewed on the subject’s 
paired (before and after presented in a blinded fashion) global photographs of the vertex 
target area at Week 24 and measured by the distribution of SSA scores  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
40 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
41 
GDD-TA-T-004 v2015.10 
 
• Independent Global Panel Review o
 
 
 
 
 
 
  
 
 
7.3 
Hypothesis and Methods of Analysis 
Finasteride subjects enrolled prior to protocol Amendment 1 will be summarized alone and will 
not be included in the analysis models. Hypothesis testing will be 2-tailed with a significance 
level of 0.05. Comparisons of setipiprant tablets 1000 mg BID versus placebo BID will be made. 
For all efficacy analyses, no adjustment of significance levels will be made for multiplicity of 
treatment comparisons. 
7.3.1 
Primary Efficacy Analyses 
For analyses of TAHC, the following set of hypotheses will be used to compare setipiprant 
tablets 1000 mg BID versus placebo BID: 
• Null hypothesis: There is no difference between setipiprant tablets 1000 mg BID and placebo 
BID in increasing TAHC (terminal hairs in a 1 cm2circular area) as measured by the change 
from baseline at Week 24 using digital image analysis. 
• Alternative hypothesis: There is a difference between setipiprant tablets 1000 mg BID and 
placebo BID in increasing TAHC (terminal hairs in a 1 cm2 circular area) as measured by the 
change from baseline at Week 24 using digital image analysis. 
For analyses of the SSA, the following set of hypotheses will be used to compare setipiprant 
tablets 1000 mg BID versus placebo BID: 
• Null hypothesis: There is no difference between setipiprant tablets 1000 mg BID and placebo 
BID in SSA (blinded) of hair growth from baseline at Week 24. 
• Alternative hypothesis: There is a difference between setipiprant tablets 1000 mg BID and 
placebo BID in SSA (blinded) of hair growth from baseline at Week 24. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
42 
GDD-TA-T-004 v2015.10 
 
Change from baseline in TAHC at Week 24 and SSA of the change of hair growth from baseline 
at Week 24 will be analyzed using an analysis of covariance (ANCOVA) model with treatment as 
a fixed effect and age and baseline value as covariates (if applicable). The treatment difference 
(setipiprant tablets 1000 mg BID versus placebo BID) will be constructed based on this 
ANCOVA model, along with the 2-sided p-value. Finasteride subjects enrolled prior to protocol 
Amendment 1 will be summarized alone and will not be included in the analysis models. 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
43 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
7.3.3 
Safety Analyses 
Adverse events will be coded from the verbatim text into preferred term (PT) and primary 
system organ class (SOC) by using the Medical Dictionary for Regulatory Activities. The 
number and percent of subjects reporting treatment-emergent AEs at least once regardless of 
causality will be tabulated. Similarly, treatment-related AEs will be tabulated. The tables will be 
generated by primary SOC and PT as well as by severity. 
Safety data will be summarized by frequency distributions or descriptive statistics and described 
in the detailed analysis plan. 
 
 
 
 
 
 
7.4 
Other Analyses 
Subject disposition, demographic data, and variables relating to the conduct of the study (eg, 
number of subjects attending each visit) will be summarized overall and by treatment. All data 
will be listed. The number of subjects enrolled will be summarized, overall and by treatment 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
44 
GDD-TA-T-004 v2015.10 
 
 
 
7.5 
Sample Size Calculation 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.6 
Interim Analyses 
No interim analyses are planned.  
8. 
Study Visit Schedule and Procedures 
Please see Figure 1 for a flow diagram of study design. Table 1 provides the schedule of visits 
and procedures. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
45 
GDD-TA-T-004 v2015.10 
 
8.1 
Subject Entry Procedures 
8.1.1 
Overview of Entry Procedures 
Prospective subjects as defined by the criteria in Section 4.3 and Section 4.4 (inclusion/exclusion 
criteria) will be considered for entry into this study. 
8.1.2 
Informed Consent and Subject Privacy  
The study will be discussed with the subject, and a subject wishing to participate must give 
informed consent prior to any study-related procedures or change in treatment. The subject must 
also give authorization and other written documentation in accordance with the relevant country 
and local privacy requirements (where applicable) prior to any study-related procedures or 
change in treatment. 
Each subject who provides informed consent will be assigned a subject number via the IWRS 
that will be used on subject documentation throughout the study. 
 
 
 
  
 
 
 
 
  
 
 
8.3 
Procedures for Final Study Entry 
A subject is considered to have entered the study once the informed consent form is signed at the 
time of screening.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
46 
GDD-TA-T-004 v2015.10 
 
8.4 
Instructions for the Subjects 
Subjects will be instructed to self-administer the setipiprant tablets 1000 mg BID or placebo BID 
orally with water at least 1 hour before or 2 hours after eating, eg, 1 hour before breakfast in the 
morning and at least 2 hours after dinner. 
 
 
In addition, subjects will be required to follow further instructions outlined in Section 4.5.3 and 
in the procedure manual.  
8.5 
Unscheduled Visits 
If a subject is seen for an unscheduled visit, an assessment and record of AEs should be 
completed. Additional examinations may be performed as necessary to ensure the safety and 
well-being of patients during the study. The eCRFs should be completed for each unscheduled 
visit. 
8.6 
Compliance With Protocol 
At Weeks 
 24 clinic visits, site personnel will reconcile subject drug usage reports 
with inspection of wallets (setipiprant or placebo) returned by the subject (ie, numbers of open 
blisters, unused tablets in any blister, and unopened blisters) in the subject’s weekly supplies to 
document the level of subject compliance with the dosing schedule. 
 
Study drug 
inventory and accountability records must be kept current and available for review by the clinical 
site monitor. All used and unused
 for setipiprant or placebo should remain with their 
weekly wallet for reconciliation with reported usage (see above). Authorized study personnel, 
with the monitor’s guidance, are responsible to reconcile any discrepancies. 
If the subject is noncompliant with the dosing schedule (eg, frequent or lengthy periods of 
missed doses, overdosing), additional treatment kits will not be dispensed (ie, the subject may be 
discontinued from study drug treatment at the investigator's discretion after consultation with the 
sponsor). 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
47 
GDD-TA-T-004 v2015.10 
 
8.7 
Early Discontinuation of Subjects 
Subjects may voluntarily withdraw from the study at any time. Notification of early subject 
discontinuation from the study and the reason for discontinuation will be made to the sponsor 
and will be clearly documented on the appropriate case report form. 
8.8 
Withdrawal Criteria 
A subject should be withdrawn from the study if the subject wishes to discontinue, or 
experiences an AE or has an abnormal laboratory result where, in the judgment of the 
investigator, continuation in the study would be detrimental to the subject’s health. Whenever 
possible, the decision to withdraw a subject from the study or study treatment should be 
discussed with the sponsor prior to discontinuation of the subject.  
8.9 
Study Termination 
The study may be stopped at his/her study site at any time by the site investigator. The sponsor 
may stop the study (and/or the study site) for any reason with appropriate notification. 
9. 
Adverse Events 
Adverse events occurring during the study will be recorded on an AE case report form. If AEs 
occur, the first concern will be the safety of the study participants. 
9.1 
Definitions 
9.1.1 
Adverse Event 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. In addition, during the screening period, AEs will be assessed regardless of the 
administration of a pharmaceutical product. 
Note: Adverse events must be collected once informed consent has been obtained, regardless of 
whether or not the subject has been administered study drug. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
48 
GDD-TA-T-004 v2015.10 
 
Progression of treatment indication including new or worsening of anticipated clinical signs or 
symptoms, which are collected as clinical efficacy variables and assessed as unequivocally 
associated with the disease progression and/or lack of efficacy, should NOT be reported as AEs 
unless the disease progression is greater than anticipated in the natural course of the disease. 
Adverse events will be assessed, documented, and recorded in the CRF throughout the study (ie, 
after informed consent has been obtained).
 
 
 
. All reported AEs will be documented on the appropriate case report form. 
9.1.2 
Serious Adverse Event 
A serious AE is any AE occurring at any dose that results in any of the following outcomes: 
death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, 
a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important 
medical events that may not result in death, be life-threatening, or require hospitalization may be 
considered a serious AE when, based upon appropriate medical judgment, they may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent 1 of the 
outcomes listed in this definition. (See Section 9.3 for procedures for reporting a serious AE.) 
The sponsor considers all cancer AEs as serious AEs.  
Preplanned surgeries or procedures for pre-existing, known medical conditions for which a 
subject requires hospitalization is not reportable as a serious AE. 
Any preplanned surgery or procedure should be clearly documented in the site source documents 
by the medically qualified investigator at the time of the subject’s entry into the study. If it has 
not been documented at the time of the subject’s entry into the study, then it should be 
documented as a serious AE and reported to the sponsor. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
49 
GDD-TA-T-004 v2015.10 
 
9.1.3 
Severity 
A clinical determination will be made of the intensity of an AE. The severity assessment for a 
clinical AE must be completed using the following definitions as guidelines: 
Mild 
Awareness of sign or symptom, but easily tolerated 
Moderate 
Discomfort enough to cause interference with usual activity 
Severe 
Incapacitating with inability to work or do usual activity 
Not applicable 
In some cases, an AE may be an all or nothing finding which cannot be 
graded. 
9.1.4 
Relationship to Study Drug or Study Procedure 
A determination will be made of the relationship (if any) between an AE and the study drug or 
study procedure, as applicable. A causal relationship is present if a determination is made that 
there is a reasonable possibility that the AE may have been caused by the drug or study 
procedure. 
9.2 
Procedures for Reporting Adverse Events 
Any AE must be recorded on the appropriate case report form. 
All AEs that are drug-related and unexpected (not listed as treatment-related in the current 
investigator's brochure) must be reported to the governing institutional review board/independent 
ethics committee (IRB/IEC) as required by the IRB/IEC, local regulations, and the governing 
health authorities. An AE that is marked ongoing at the exit visit may need to be followed up as 
appropriate.  
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
50 
GDD-TA-T-004 v2015.10 
 
In the event of a serious AE, the investigator must: 
1. Notify the sponsor immediately by fax or email using the serious AE form (contact details can 
be found on page 1 of the serious AE form); phone numbers and relevant sponsor’s personnel 
contacts are also on the front page of protocol and study contacts page. 
2. Obtain and maintain in his/her files all pertinent medical records, information, and medical 
judgments from colleagues who assisted in the treatment and follow-up of the subject. 
3. Provide the sponsor with a complete, written description of the AE(s) on the serious AE form 
describing the event chronologically, including any treatment given (eg, medications 
administered, procedures performed) for the AE(s). Summarize relevant clinical information 
about the event: signs, symptoms, diagnosis, clinical course and relevant clinical laboratory 
tests, etc. Include any additional or alternative explanation(s) for the causality which includes 
a statement as to whether the event was or was not related to the use of the investigational 
drug. 
4. Promptly inform the governing IRB/IEC of the serious AE as required by the IRB/IEC, local 
regulations, and the governing health authorities. 
 
 
 
 
 
 
 
 
 
The treatment assignment for the subject can be determined by designated site personnel logging 
into the IWRS system via password protected access. The reason for breaking the code must be 
recorded in the subject’s source documents. 
10. 
Administrative Items 
This protocol is to be conducted in accordance with the applicable GCP regulations and 
guidelines, eg, the ICH Guideline on GCP. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
51 
GDD-TA-T-004 v2015.10 
 
10.1 
Protection of Human Subjects 
10.1.1 
Compliance with Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations 
Written informed consent is to be obtained from each subject prior to any study-related activities 
or procedures in the study, and/or from the subject's legally authorized representative.  
10.1.2 
Compliance With IRB or IEC Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) or 
applicable IEC regulations. The investigator must obtain approval from a properly constituted 
IRB/IEC prior to initiating the study and re-approval or review at least annually. The sponsor is 
to be notified immediately if the responsible IRB/IEC has been disqualified or if proceedings 
leading to disqualification have begun. Copies of all IRB/IEC correspondence with the 
investigator should be provided to the sponsor. 
10.1.3 
Compliance With Good Clinical Practice 
This protocol is to be conducted in accordance with the applicable GCP regulations and 
guidelines. 
10.1.4 
Compliance With Electronic Records; Electronic Signatures 
Regulations (US 21CFR Part 11) 
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. 
10.2 
Changes to the Protocol 
The investigator must not implement any deviation from or changes of the protocol without 
approval by the sponsor and prior review and documented approval/favorable opinion from the 
IRB/IEC of a protocol amendment, except where necessary to eliminate immediate hazards to 
study subjects, or when the changes involve only logistical or administrative aspects of the study 
(eg, change in monitors, change of telephone numbers). 
10.3 
Subject Confidentiality 
A report of the results of this study may be published or sent to the appropriate health authorities 
in any country in which the study drug may ultimately be marketed, but the subject’s name will 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
52 
GDD-TA-T-004 v2015.10 
 
not be disclosed in these documents. The subject's name may be disclosed to the sponsor of the 
study, Allergan, or the governing health authorities or the FDA if they inspect the study records. 
Appropriate precautions will be taken to maintain confidentiality of medical records and personal 
information. 
10.3.1 
Subject Privacy 
Written authorization and other documentation in accordance with the relevant country and local 
privacy requirements (where applicable) is to be obtained from each subject prior to enrollment 
into the study, and/or from the subject's legally authorized representative in accordance with the 
applicable privacy requirements (eg, HIPAA). 
In accordance with HIPAA requirements, additional purposes of this study may include 
publishing of anonymous patient data from the study. 
10.4 
Documentation 
10.4.1 
Source Documents 
Source documents may include a subject's medical records, hospital charts, clinic charts, secure 
digital cards, photographs, patient-reported outcomes, the investigator's subject study files, as 
well as the results of diagnostic tests 
. The 
investigator's copy of the case report forms serves as part of the investigator's record of a 
subject's study-related data.  
The following information should be entered into the subject's medical record: 
• Subject’s name 
• Subject’s contact information 
• Date that the subject entered the study, subject number, and subject randomization (or 
medication kit[s]) number 
• Study title and/or protocol number of the study and the name of the sponsor 
• A statement that informed consent was obtained (including the date) and a statement that 
written authorization or other country and local subject privacy required documentation for 
this study has been obtained (including the date) 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
53 
GDD-TA-T-004 v2015.10 
 
• Dates of all subject visits 
• Medical history, including HIV status 
• Eligibility criteria 
• Count of returned study medication 
• Record of all hair products used by the subject 
• Date the subject exited the study and a notation as to whether the subject completed the study 
or reason for discontinuation 
• Date of global and macrophotography (and approval of global photography at screening) 
• All subject and investigator assessments 
• Physical examination 
• Vital sign measurements 
• All concomitant medications (List all prescription and nonprescription medications being 
taken at the time of enrollment. At each subsequent visit, changes to the list of medications 
should be recorded.) 
• Occurrence and status of any AEs 
 
 
 
 
• Modified Norwood-Hamilton classification 
• Global photographs 
• Macrophotographs 
10.4.2 
Case Report Form Completion 
The investigator is responsible for ensuring that data are properly recorded on each subject's case 
report forms and related documents. An investigator who has signed the protocol signature page 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
54 
GDD-TA-T-004 v2015.10 
 
should personally sign for the case report forms (as indicated in the case report forms) to ensure 
that the observations and findings are recorded on the case report forms correctly and 
completely. The case report forms are to be submitted to the sponsor in a timely manner at the 
completion of the study, or as otherwise specified by the sponsor and will be maintained in a 
central data repository. 
10.4.3 
Study Summary 
An investigator's summary will be provided to the sponsor within a short time after the 
completion of the study, or as designated by the sponsor. A summary is also to be provided to the 
responsible IRB/IEC. 
10.4.4 
Retention of Documentation 
All study-related correspondence, subject records, consent forms, subject privacy documentation, 
records of the distribution and use of all investigational products, and copies of case report forms 
should be maintained on file. 
For countries falling within the scope of the ICH guidelines, the sponsor-specific essential 
documents should be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the investigational product. These documents should be retained for a 
longer period, however, if required by the applicable regulatory requirement(s) or if needed by 
the sponsor. 
The sponsor requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually agreed upon arrangements can be made for transfer of 
ownership to a suitably qualified, responsible person. 
10.5 
Labeling, Packaging, and Return or Disposal of Study 
drugs/Treatments 
10.5.1 
Labeling/Packaging 
Setipiprant and placebo will be packaged 
 and 
combined into a weekly wallet. Each weekly wallet of setipiprant or placebo will contain a total 
of 14 doses (ie, a week’s worth of BID dosing). The investigator will dispense an appropriate 
number of weekly wallets for the time interval until the subject’s next clinic visit.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
55 
GDD-TA-T-004 v2015.10 
 
As this is a double-blind study, labeling of the subject treatment kit will not show the treatment 
allocation. All other information required by regulation will appear on each treatment kit. 
10.5.2 
Clinical Supply Inventory 
The investigator must keep an accurate accounting of the number of investigational units 
received from the sponsor, dispensed to the subjects, the number of units returned to the 
investigator by the subject (if applicable), and the number of units returned to the sponsor during 
and at the completion of the study. A detailed inventory must be completed for the study drug. 
The study drug must be dispensed only by appropriately qualified site personnel to subjects in 
the study. The medication is to be used in accordance with the protocol for subjects who are 
under the direct supervision of an investigator. 
10.5.3 
Return or Disposal of Study Drugs and/or Supplies 
All clinical study drugs/treatments and/or supplies will be returned to the sponsor or sponsor 
designee for destruction. 
10.6 
Monitoring by the Sponsor 
A representative of the sponsor will monitor the study on a periodic basis. The determination of 
the extent and nature of monitoring will be based on considerations such as the objective, 
purpose, design, complexity, blinding, size, and endpoints of the study. 
Authorized representatives of the sponsor or regulatory authority representatives will conduct 
onsite visits to review, audit and copy study-related documents. These representatives will meet 
with the investigator(s) and appropriate staff at mutually convenient times to discuss study-
related data and questions. 
 
 
 
 
 
  
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
56 
GDD-TA-T-004 v2015.10 
 
 
   
 
 
 
. All samples will be returned to the 
sponsor or sponsor designee at the completion of the study. The sponsor shall have full 
ownership rights to any biological specimens/samples derived from the study.  
Details about the handling of 
 are provided in the study laboratory 
manual.  
10.8 
Publications 
The sponsor as the sponsor has proprietary interest in this study. Authorship and manuscript 
composition will reflect joint cooperation between multiple investigators and sites and the 
sponsor personnel. Authorship will be established prior to the writing of the manuscript. As this 
study involves multiple centers, no individual publications will be allowed prior to completion of 
the final report of the multicenter study except as agreed with the sponsor. 
10.9 
Coordinating Investigator 
A signatory coordinating investigator will be designated prior to the writing of the clinical study 
report. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
57 
GDD-TA-T-004 v2015.10 
 
11. 
References 
Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride 
for androgenetic alopecia. J Dermatol. 2002;29(10):665-669. 
Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 
1996;14(4):713-721. 
Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 
1999;17(2):261-269. 
Caruso D, Abbiati F, Giatti S, et al. Patients treated for male pattern hair with finasteride show, 
after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and 
plasma. J Steriod Biochem Mol Biol. 2015;146:74-79. 
Colombe L, Michelet JF, Bernard, BA. Prostanoid receptors in anagen human hair follicles. Exp 
Dermatol. 2008;17(1):63-72. 
Cotsarelis G, Zheng Y, Hsieh J. Evaluation of DP-2 antagonists in promotion of hair growth. 
Philadelphia: University of Pennsylvania; 2015a. 
Cotsarelis G, Zheng Y, Hsieh J. Demonstration that setipiprant effectively prevents PGD 
induced hair growth inhibition in human hair follicle mini organ cultures. Philadelphia: 
University of Pennsylvania; 2015b. 
DiLoreto C, LaMarra F, Mazzon G, Belgrano E, Trombetta C, Cauci S. Immunohistochemical 
Evaluation of Androgen Receptor and Nerve Structure Density in Human Prepuce from Patients 
with Persistent Sexual Side Effects after finasteride Use for Androgenetic Alopecia. PLOS One. 
2014;9(6):e100237. 
Falto-Aizpurua L, Choudhary S, Tosti A. Emerging treatments in alopecia. Expert Opin Emerg 
Drugs. 2014;19(4):545-556. 
Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald 
scalp of men with androgenetic alopecia. Science Transl Med. 2012;4(126):126ra34-126ra34.  
Harcha G, Martinez B, Tsai TF, et al. A randomized, active- and placebo-controlled study of the 
efficacy and safety of different doses of dutasteride versus placebo and finasteride in the 
treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-
498.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
58 
GDD-TA-T-004 v2015.10 
 
McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic 
alopecia. Skin Therapy Lett. 2012;17(6):1-4. 
Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68:1359-
1365. 
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in 
the treatment of male pattern hair loss: results of a randomized placebo-controlled study of 
dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.  
Savin RC. Evaluating androgenetic alopecia in male and female patients: an improved visual 
method of classifying and tracking hair loss using computer-generated male and female pattern 
and density scales. Kalamazoo, MI: The Upjohn Company; 1993.  
Severi G, Sinclair R, Hopper JL, et al. Androgenetic alopecia in men aged 40–69 years: 
prevalence and risk factors. Br J Dermatol. 2003;149(6):1207-1213. 
Sinclair R. Fortnightly review: male pattern androgenetic alopecia. Br Med J. 
1998;317(7162):865-869. 
Stough D, Stenn K, Haber R, et al. Psychological effect, pathophysiology, and management of 
androgenetic alopecia in men. Mayo Clinic Proceedings Proc. 2005;80(10):1316-1322. 
Tabolli S, Sampogna F, di Pietro C, Mannooranparampil TJ, Ribuffo M, Abeni D. Health status, 
coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. 
Am J Clin Dermatol. 2013;14(2):139-145. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
59 
GDD-TA-T-004 v2015.10 
 
12. 
Attachments  
12.1 
Examination Procedures, Tests, Equipment, and Techniques 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
60 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
61 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
62 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
63 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
64 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
o 
 
 
 
 
 
  
o 
 
  
 
 
 
 
  
 
 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
65 
GDD-TA-T-004 v2015.10 
 
o 
 
 
  
 
  
o 
 
  
o 
 
  
o 
 
o 
 
  
o 
 
 
  
 
  
o 
 
 
 
  
o 
 
 
 
  
o 
 
 
  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
66 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
  
 
  
 
 
 
 
 
  
 
 
 
  
.  


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
67 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
68 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
   
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
69 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
 
r 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
70 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
71 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
72 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
73 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
74 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
75 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
76 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
77 
GDD-TA-T-004 v2015.10 
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
78 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
 
 
  
 
 
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
79 
GDD-TA-T-004 v2015.10 
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
80 
GDD-TA-T-004 v2015.10 
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
   
 
  
 
  
 
 
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
81 
GDD-TA-T-004 v2015.10 
 
  
 
   
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
82 
GDD-TA-T-004 v2015.10 
 
  
 
  
 
  
 
  
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
83 
GDD-TA-T-004 v2015.10 
 
 
 
 
  
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
84 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
  
   
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
85 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
86 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
87 
GDD-TA-T-004 v2015.10 
 


 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
88 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
89 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
90 
GDD-TA-T-004 v2015.10 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
91 
GDD-TA-T-004 v2015.10 
 
12.2 
Safety Measures 
• Adverse events 
The investigator will question the subject in order to ascertain whether any AEs were 
experienced since the previous visit. All pertinent information regarding AEs (ie, date of onset 
and stop, duration, outcome, severity, relationship to study drug, action or treatment required) 
will be obtained and recorded in the source documents and appropriately transcribed on the 
eCRF page. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
92 
GDD-TA-T-004 v2015.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
.


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
93 
GDD-TA-T-004 v2015.10 
 
12.3 
Glossary of Abbreviations 
Term/Abbreviation 
Definition 
5AR 
5α-reductase 
AE 
adverse event 
AGA 
androgenetic alopecia 
 
 
ALT 
alanine aminotransferase 
ANCOVA 
analysis of covariance 
ASA 
Alopecia Symptom Assessment 
AST 
aspartate aminotransferase 
 
 
 
 
 
 
 
AUC0-inf 
area under the concentration-time curve from time 0 to infinity 
BID 
twice daily 
bpm 
beats per minute 
 
 
CMH 
Cochran-Mantel-Haenszel 
CRTH2 
chemoattractant receptor-homologous molecule expressed on T helper 
2 cells 
 
 
eCRF 
electronic case report form 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
human immunodeficiency virus 
 
 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
 
 
 
 
 
 
 
IRB 
Institutional Review Board 
IWRS 
interactive web response system 
LOCF 
last observation carried forward 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
94 
GDD-TA-T-004 v2015.10 
 
MSP 
medical safety physician 
mITT 
modified intent-to-treat 
NHS 
Norwood-Hamilton Hair Loss Scale 
PGD2 
prostaglandin D2 
 
 
PT 
preferred term 
PTGDS 
prostaglandin-D2 synthase 
ptgs2 
mouse prostaglandin-D2 synthase homolog 
 
 
 
 
 
 
 
 
 
 
SOC 
system organ class 
SSA 
Subject Self-Assessment 
 
  
TAHC 
target area hair count 
 
 
 
 
TBL 
total bilirubin 
 
 
ULN 
upper limits of normal 
WBC 
white blood cell 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
95 
GDD-TA-T-004 v2015.10 
 
12.4 
Protocol Amendment Summary 
Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of 
Setipiprant Tablets in Androgenetic Alopecia in Males With a Comparator Arm 
Protocol 1922-201-002 Amendment 1 
Date of Amendment: February, 2017 
Amendment Summary 
This summary includes changes made to the original Protocol 1922-201-002 (25 March 2016). 
This protocol was amended to remove the finasteride arm, expand the upper range of the study 
population to age 49 years, and to remove some of the exclusionary concomitant medications. It 
is anticipated that these changes that are designed to simplify the protocol will result in an 
increased rate of study enrollment. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes. Minor editorial and document formatting 
revisions have not been summarized. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
96 
GDD-TA-T-004 v2015.10 
 
Section 
Revision 
Rationale 
Protocol Title Page 
Deleted “With a Comparator Arm” 
from study title. 
Finasteride arm deleted. Data from 
the small number of finasteride 
subjects enrolled prior to protocol 
Amendment 1 will not be 
compared to other treatment 
groups. 
Protocol Title Page 
Revised fax number for Allergan 
Medical Safety Physician 
Previous fax number was incorrect. 
Protocol Summary, 
Study Objectives 
Revised overall age range of 
subjects in the setipiprant and 
placebo groups from 18 - 41 to 18 - 
49 years.  
Deleted finasteride arm. 
To increase the rate of study 
enrollment. 
Removed finasteride arm to 
simplify study design, allowing the 
age range to be expanded to up to 
49 years. The finasteride arm was 
deemed not critical in determining 
the efficacy or safety of setipiprant. 
Protocol Summary, 
Study Design, Structure 
Deleted finasteride arm. 
To be consistent with the removal 
of the finasteride arm. 
Protocol Summary, 
Study Design, Control 
Deleted finasteride arm. 
See rationale above. 
Protocol Summary, 
Study Design, 
Dosage/Dose Regimen 
Deleted finasteride arm 
See rationale above. 
Protocol Summary, 
Study Design, 
Enrollment/Stratification 
Deleted finasteride arm. Changed 
the randomization ratio for 
 
 
(setipiprant:placebo:finasteride) to 
1:1 (setipiprant:placebo). Changed 
the age range for stratification from 
35 – 41 years to 35 - 49 years.  
See rationale above. 
To be consistent with the revised 
study population. 
Protocol Summary, 
Study Population 
Characteristics, Key 
Inclusion Criteria  
Expanded the age range from 18 – 
41 years to 18 - 49 years.  
To be consistent with the revised 
study population. 
Protocol Summary, 
General Statistical 
Methods and Types of 
Analyses 
Deleted pairwise comparison of 
finasteride and placebo. 
Added finasteride subjects will be 
summarized alone. 
Finasteride arm was removed.  
To address how data from subjects 
treated with finasteride prior to 
protocol Amendment 1 will be 
analyzed. 
Protocol Summary, 
General Statistical 
Methods and Types of 
Analyses, Efficacy 
Analyses 
Added the finasteride group is 
excluded from analysis. 
Changed the age stratification in 
efficacy analysis model from 18 - 
34 and 35 - 41 years to < 35 and 
≥ 35 years. 
For clarification. 
To include those in the 42 - 
49 years age group (ie, ≥ 35 years) 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
97 
GDD-TA-T-004 v2015.10 
 
Section 
Revision 
Rationale 
Protocol Summary, 
General Statistical 
Methods and types of 
Analyses, Sample Size 
Calculation 
Deleted finasteride arm (n = 35). 
Reduced enrollment target for 
setipiprant and placebo from 187 to 
152 subjects and 
enrollment 
target from 175 to 140 subjects.  
Randomization ratio for 
 
subjects changed from 2:2:1 
(setipiprant:placebo:finasteride) to 
1:1 (setipiprant:placebo). 
Finasteride arm removed. 
 
 
 
 
 
 
. 
1 Background and 
Clinical Rationale 
Deleted the finasteride arm. 
To be consistent with the removal 
of the finasteride arm. 
2.1 Study Objectives 
Revised overall age range of 
subjects in the setipiprant and 
placebo groups from 18 - 41 to 18 - 
49 years.  
Deleted finasteride arm. 
See rational above. 
3 Study Design 
Deleted finasteride arm.  
Deleted requirement for blinded 
investigator to give efficacy 
assessments to finasteride subjects 
while subject/staff are unblinded. 
 
 
 
Removed finasteride arm.  
4.1 Number of Subjects 
Deleted finasteride arm (n = 35); 
changed number of setipiprant and 
placebo subjects from 187 to 152. 
 
 
 
 
 
  
Removed the finasteride arm. 
Increased overall age range of 
subjects in the setipiprant and 
placebo groups from 18 - 41 to 18 - 
49 years. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
98 
GDD-TA-T-004 v2015.10 
 
Section 
Revision 
Rationale 
4.2 Study Population 
Characteristics 
Revised overall age range of 
subjects in the setipiprant and 
placebo groups from 18 - 41 to 18 - 
49 years.  
Noted that subjects were assigned to 
finasteride under the original 
protocol. 
To increase the rate of study 
enrollment. 
For clarification. 
4.3 Inclusion Criteria, 3 
Expanded the age range from 18 – 
41 years to 18 – 49 years. 
To be consistent with the revised 
study population. 
4.3 Inclusion Criteria, 6 
Revised the required maintenance 
of hair length from ≥ 2.54 cm (1 in) 
to ≥ 2 cm (0.75 in).  
To increase the rate of study 
enrollment 
4.4 Exclusion Criteria, 3 
The Criterion 3 list was re-lettered 
from 3a – e to 3a – f. 
Added a criterion. 
 
 
 
  
 
 
 
 
4.4 Exclusion Criteria, 4 
The Criterion 4 list was re-lettered 
from 4a–e to 4a-c 
Removed criteria. 
4.4 Exclusion Criteria; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.3 Special Activities 
Deleted finasteride information. 
See rationale above. 
5.2 Control Treatments 
Deleted finasteride information. 
See rationale above. 
5.3 Methods for 
Masking/Blinding 
Deleted information about 
unblinded finasteride subjects/site 
staff and blinded investigator to 
perform efficacy assessments. 
See rationale above. 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
99 
GDD-TA-T-004 v2015.10 
 
Section 
Revision 
Rationale 
5.4 Treatment 
Allocation Ratio and 
Stratification 
Deleted finasteride arm. Changed 
number of
 subjects from 
175 to 140. 
Changed the randomization ratio for 
 subjects from 2:2:1 
(setipiprant:placebo:finasteride) to 
1:1 (setipiprant:placebo). Added 
non-PK subjects to be stratified by 
age, 18 -34 and 35 – 49 years.  
To be consistent with Section 4.1 
5.5 Method for 
Assignment to 
Treatment 
Groups/Randomization 
Deleted finasteride arm (n = 35). 
Changed number of 
 
subjects from 175 to 140. Changed 
 randomization ratio from 
2:2:1 
(setipiprant:placebo:finasteride) to 
1:1 (setipiprant:placebo). 
To be consistent with Sections 4.1 
and 5.4. 
5.6 Treatment Regimen 
and Dosing 
Added subjects assigned to 
finasteride prior to protocol 
Amendment 1 should continue 
treatment until they complete the 
study. 
Deleted information about 
finasteride regimen. 
For clarification. 
5.7 Storage of Study 
Drugs 
Deleted information about 
finasteride risk to pregnant or 
potentially pregnant women 
See rationale above. 
5.9 Treatment 
Administration 
Deleted finasteride packaging, 
dosing, and open-label information. 
See rationale above. 
6.1 Efficacy Measures 
Deleted finasteride blinding 
information. 
See rationale above. 
 
 
. 
7.3 Hypothesis and 
Methods of Analysis 
Deleted pairwise comparison of 
finasteride and placebo. 
Added that finasteride subjects will 
be summarized alone. 
Finasteride arm was removed.  
To address how data from subjects 
treated with finasteride prior to 
protocol Amendment 1will be 
analyzed. 
7.3.1 Primary Efficacy 
Analyses 
Added finasteride subject data will 
be summarized alone. 
See rationale above. 
 
 
 
 
 


 
 
Approval Date: 
 
17-Feb-2017
Allergan Confidential 
Protocol 1922-201-002 Amendment 1 
 
 
100 
GDD-TA-T-004 v2015.10 
 
Section 
Revision 
Rationale 
7.5 Sample Size 
Calculation 
Deleted finasteride arm (n = 35) and 
related text. 
Deleted Finasteride versus Placebo 
column from Table 2. 
Removed finasteride arm. 
 
 
 
 
 
 
 
 
 
8.3 Procedures for Final 
Study Entry 
Changed time subject has entered 
the study from time of 
randomization (Day 1) to screening. 
Correction as informed consent 
form is signed at screening. 
8.4 Instructions for the 
Subjects 
Deleted instructions for finasteride 
group. 
Removed finasteride arm. 
8.6 Compliance With 
Protocol 
Deleted finasteride bottle 
information. 
See rationale above. 
10.5.1 
Labeling/Packaging 
Deleted finasteride information. 
See rationale above. 
 


 
 
Approval Date: 
 
17-Feb-2017
ALLERGAN 
 
 
 
 
 
 
 
 
 
Date (DD/MMM/YYYY)/Time (PT) 
Signed by: 
Justification 
  
 
 
            
 
           
 
            
 
           
 
            
 
           
 
     
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
 
Protocol 1922-201-002 Amd 1

SAP_001.pdf: 
NCT02781311 
 
Study ID: 1922-201-002  
 
Title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
PHASE 2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN 
MALES 
 
Statistical Analysis Plan Amendment 2 Date: 25‐Jul‐2018 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
1 
 
1. 
Title Page 
STATISTICAL ANALYSIS PLAN 
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
PHASE 2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN 
MALES 
Original: 2017-APR-17 
Amendment 2: 2018-JUL-25 
Protocol Number: 
1922-201-002 
Development Phase: 
2A 
Product Name: 
Setipiprant Tablets 
Study Statistician: 
 
Sponsor: 
Allergan, Inc. 
2525 Dupont Drive 
Irvine, California USA 
92612 
+1-714-246-4500 
+1-800-347-4500 
 
This document is the property of Allergan, Inc. and may not, in full or part, be passed on, 
reproduced, published, distributed to any person, or submitted to any regulatory authority 
without the express written permission of Allergan, Inc.


Allergan C
Setipiprant
 
2. 
T
1. 
Title
2. 
Tabl
 
2.1
 
2.2
3. 
List 
4. 
Intro
 
4.1
 
4.3
5. 
Stati
 
5.1
 
5.2
6. 
Data
 
6.1
 
6.3
 
6.4
 
6.5
Confidential 
t Tablets 
Table of Co
e Page .........
le of Content
List of Tab
List of Fig
of Abbrevia
oduction ......
Primary St
Schedule o
istical Metho
Statistical 
5.1.1  Sta
5.1
5.1
5.1
5.1
5.1
5.1
5.1.2  De
Changes in
5.2.1  Ch
5.2.2  Ch
a Handling a
Study Trea
6.1.1  An
6.1.2  Mi
Missing D
Missing/In
6.4.1  Mi
6.4.2  Mi
Imputation
ontents 
...................
ts ................
bles .............
gures ...........
ations and De
...................
tudy Objecti
of Activities 
odology and
Methods Pla
atistical and A
.1.1  Comm
.1.2  Demo
.1.3  Effica
.1.4  Safety
.1.5  Subgr
.1.6  Interim
etermination 
n the Condu
hanges in the
hanges to An
and Analysis 
atment Conv
nalysis Days 
issing/Incom
Date Informat
ncomplete D
issing/Incom
issing/Incom
n of Primary
....................
....................
....................
....................
efinition of T
....................
ives and Des
...................
d Study Endp
anned in the
Analytical P
mon Conven
ographics an
acy Analyses
y Analyses ..
roup Analyse
m Analyses .
of Sample S
ct of the Stu
e Conduct of
nalyses Prior 
Convention
ventions .......
...................
mplete Treatm
tion for Adv
Date for Prior
mplete Start D
mplete End D
y Efficacy M
2 
....................
....................
....................
....................
Terms ..........
....................
sign .............
....................
points ...........
 Protocol an
Plans ............
ntions ...........
nd Other Bas
s ..................
....................
es ................
....................
Size .............
udy or Planne
f the Study ...
to Database
ns .................
....................
....................
ment End Da
verse Events.
r and Concom
Date .............
Date ..............
Measurements
....................
....................
....................
....................
....................
....................
....................
....................
....................
nd Determina
....................
....................
seline Charac
....................
....................
....................
....................
....................
ed Analyses
....................
e Lock .........
....................
....................
....................
ate ...............
....................
mitant Medi
....................
....................
s (TAHC and
....................
....................
....................
....................
....................
....................
....................
....................
....................
ation of Sam
....................
....................
cteristics .....
....................
....................
....................
....................
....................
 ...................
....................
....................
....................
....................
....................
....................
....................
ications .......
....................
....................
d SSA) ........
SAP 1922-20
....................
....................
....................
....................
....................
....................
....................
....................
....................
mple Size .....
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
01-002 
...... 1 
...... 2 
...... 3 
...... 3 
...... 4 
...... 6 
...... 6 
...... 8 
.... 11 
.... 11 
.... 11 
.... 11 
.... 13 
.... 14 
.... 20 
.... 23 
.... 23 
.... 23 
.... 24 
.... 24 
.... 24 
.... 24 
.... 24 
.... 24 
.... 24 
.... 25 
.... 26 
.... 26 
.... 27 
.... 28 


Allergan C
Setipiprant
 
 
6.7
7. 
Data
8. 
Refe
9. 
Ame
10.  Ame
 
 
L
2.1
Table 3-1
 
L
2.2
 
 
 
Confidential 
t Tablets 
Imputed V
a Collected b
erences ........
endment 1 ...
endment 2 ...
List of Tabl
1 
 Abbre
List of Figu
Value Listing
but Not Anal
...................
...................
...................
les 
eviations an
ures 
 
g Convention
lyzed ...........
....................
....................
....................
d Definition
3 
ns .................
....................
....................
....................
....................
ns of Terms ..
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
....................
SAP 1922-20
....................
....................
....................
....................
....................
....................
01-002 
.... 28 
.... 28 
.... 28 
.... 29 
.... 29 
...... 4 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
4 
 
3. 
List of Abbreviations and Definition of Terms 
Table 3-1 
 Abbreviations and Definitions of Terms 
Term/Abbreviation Definition 
AE 
adverse event 
AGA 
androgenetic alopecia 
 
ALT 
alanine aminotransferase 
ANCOVA 
analysis of covariance 
ASA 
Alopecia Symptom Assessment 
AST 
aspartate aminotransferase 
 
 
 
 
 
 
 
AUC0-inf 
area under the concentration-time curve from time 0 to infinity 
BID 
twice daily 
bpm 
beats per minute 
 
 
CMH 
Cochran-Mantel-Haenszel 
 
 
 
CSR 
Clinical Study Report 
 
 
eCRF 
electronic case report form 
 
 
 
 
 
 
 
 
 
LOCF 
last observation carried forward 
mITT 
 
modified intent-to-treat 
NHS 
Norwood-Hamilton Hair Loss Scale 
 
 
PT 
preferred term 
 
 
 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
5 
 
 
 
 
 
SOC 
system organ class 
SSA 
Subject Self-Assessment 
 
  
TAHC 
target area hair count 
 
 
 
 
TBL 
total bilirubin 
 
 
ULN 
upper limits of normal 
WBC 
white blood cell 


Allergan C
Setipiprant
 
4. 
In
This docu
evaluate 
twice dai
generally
separate 
The stati
and after
 
P
4.1
The obje
administr
subjects a
androgen
 w
This is a 
the effect
objective
All inves
matching
Approxim
subjects w
tablets 10
Placebo)
(< 35 and
groups w
 
 
Confidential 
t Tablets 
ntroductio
ument detail
the safety, to
ily (BID) in 
y good health
document. 
stical analys
r database loc
Primary St
ctives of thi
ration of seti
aged 18 to 4
netic alopeci
will be scree
multicenter,
t of treatmen
e (ie, imaging
stigators, site
g placebo du
mately 152 s
will be rando
000 mg BID
, and 
d ≥ 35 years)
will be about 
on 
ls the planne
olerability an
males with a
h. Specificat
sis will be co
ck.  
tudy Obje
s study are t
ipiprant tabl
49 years (inc
a with vertex
ened for eligi
, randomized
nt with setipi
g-based) and
e staff, and s
uring the stud
subjects will
omly assign
D (hereafter r
). Overall, th
80 and 72, r
 
ed analysis fo
nd efficacy o
androgenetic
tions of table
onducted afte
ectives and
o evaluate th
ets 1000 mg
lusive) at ba
x patterns II
ibility for en
d, double-bli
iprant tablet
d subjective 
subjects will 
dy. 
 be enrolled 
ed to 1 of 2
referred as Se
he number o
respectively
6 
for Study 192
of oral admin
c alopecia (A
es, figures, a
er all subject
d Design 
he safety, tol
g BID in mal
aseline, who 
Iv, IV, or V o
nrollment int
ind, placebo
s 1000 mg B
be blinded t
in up to 20 
treatment gr
etipiprant), o
f subjects en
(Figure 4-1)
22-201-002,
nistration of
AGA) who a
and data listi
ts have comp
lerability, an
les with andr
are in gener
on the NHS,
to the study.
o-controlled s
BID on scalp
- and su
to whether s
US sites. On
roups in a 1:
or placebo B
will be stra
nrolled into t
). 
 a phase 2A 
f setipiprant 
are 18 to 49 y
ings are cont
pleted or exi
nd efficacy o
rogenetic alo
ral good hea
, and are dis
study design
p hair growth
ubject-reporte
subjects rece
n Day 1, 140
1 ratio to rec
BID (hereafte
atified by ba
the setipipra
SAP 1922-20
study to 
tablets 1000
years old an
tained in a 
ited the stud
of oral 
opecia (AGA
 Male
lth, have 
ssatisfied wit
ned to determ
h as assessed
ed) measure
ive setipipra
0 eligible
ceive setipip
er referred a
aseline age g
ant and place
01-002 
0 mg 
d in 
dy 
A), 
e 
th 
mine 
d by 
es. 
ant or 
prant 
as 
roup 
ebo 


Allergan C
Setipiprant
 
This SAP
treatment
Finasteri
group wi
Confidential 
t Tablets 
P is based on
t arms – Seti
de 1 mg QD
ill be summa
n the Amend
ipiprant 100
D was remove
arized but no
dment 1 of th
00 mg BID, P
ed from Am
ot compared 
7 
he protocol. 
Placebo BID
mendment 1 o
with the oth
The original
D and Finaste
of the protoc
her treatment
l protocol ha
eride 1 mg Q
col. Data in t
t groups.  
SAP 1922-20
ad three 
QD. The 
the Finasteri
01-002 
ide 


A
S
 
Allergan Confident
Setipiprant Tablets 
tial 
8 
SAP 1922-201-002 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
9 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
10 
 


Allergan C
Setipiprant
 
5. 
S
 
S
5.1
This stati
statistica
collected
Appendix
5.1.1 S
Statistica
5.1.1.1 
5.1.1.1.
Two popu
The mIT
postbasel
efficacy d
summariz
will also 
The safet
treated su
received.
5.1.1.1.
The follo
• S
• P
• F
in
They wil
tables/lis
Confidential 
t Tablets 
Statistical M
Statistical M
Samp
istical analys
l section of t
d in the study
x 16.1.9.
Statistical a
al analyses w
Com
1 Analysi
ulations will
T population
line measure
data based o
zed and anal
be based on
ty population
ubjects), wil
.  
2 Study T
owing treatm
etipiprant 
lacebo 
inasteride: e
ncluded in an
ll be labeled 
tings.    
Methodolo
Methods P
ple Size 
sis plan (SA
the protocol 
y. The text po
and Analy
will be condu
mon Conv
s Populati
l be used in t
n, consisting
ement for 1 o
on the random
lyzed using t
n mITT popu
n, consisting
l be used for
Treatments
ment groups a
enrolled unde
ny data analy
as “Setipipr
ogy and S
Planned in
AP) will be ap
and contain
ortion of the
ytical Plan
ucted using
ventions 
ions 
the analysis:
g of all rando
of the coprim
mized treatm
the mITT po
ulation. 
g of all subje
r analyses of
s 
are defined f
er the origin
ysis models.
rant”, “Place
11 
tudy Endp
n the Proto
pproved prio
ns a detailed 
e SAP will be
ns 
: modified in
omized subje
mary efficacy
ment group. A
opulation. D
ects who rece
f all safety d
for this study
nal protocol, 
. 
ebo” and “Fin
points 
ocol and D
or to databas
description 
e included in
ntent-to-trea
ects who hav
y measures, 
All efficacy 
emographic 
eive at least 
data based on
y. 
data will be
nasteride” in
Determina
se lock. The 
of methods t
n the CSR re
at (mITT) an
ve a baseline
will be used
variables wi
 and baselin
1 dose of stu
n the actual t
 summarized
n the data su
SAP 1922-20
ation of 
SAP expand
to analyze d
eport as 
d safety.  
e and at least
d for analyse
ill be 
ne characteris
udy drug (ie
treatment 
d but not 
ummary 
01-002 
ds the 
data 
t 1 
es of 
stics 
e, all 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
12 
 
5.1.1.1.3 Statistical Methodology 
The methodologies defined below apply as specified to individual endpoints defined in this SAP. 
Finasteride subjects enrolled prior to Protocol Amendment 1 will be summarized alone and will 
not be included in the analysis models. All statistical testing will be based on 2-sided hypothesis 
tests with a statistical significance of p ≤ 0.05, unless specified otherwise. 
• Descriptive statistics include the sample size (N), mean, standard deviation (SD), median, 
minimum (Min), and maximum (Max) for continuous/ordinal data, and the sample size (N), 
frequency count, and percentage for categorical data. 
• For the analysis of ordinal-scaled categorical data, unless specified otherwise, Cochran-
Mantel-Haenszel (CMH) row mean scores test stratified by age group (< 35 and ≥35 years) 
will be used.  
• Change from baseline (CFB) will be analyzed using an analysis of covariance (ANCOVA) 
model with treatment as a fixed effect and age and baseline value as covariates (if applicable). 
The treatment difference (Setipiprant versus Placebo) will be constructed based on the 
ANCOVA model, along with the 2-sided p-value and 95% confidence intervals (CI). The 
type III sums of squares will be used for all ANCOVA models. 
5.1.1.1.4 Other Common Conventions 
• The baseline value of an assessment will be the last value recorded prior to the subject 
receiving the first dose of study medication (day 1), except for TAHC,
 
For these parameters, the baseline value is based on the nominal Visit 2 (baseline) 
macrophotography, which may include photos taken after the first dose of study drug when a 
reshoot was required to obtain evaluable baseline measurements. 
 
 
 
• In general, change from baseline is calculated as follow-up minus baseline. Between-group 
differences will be calculated for Setipiprant minus Placebo.   
• Clinical laboratory system will be presented with Standard International (SI) units.  
• Medical Dictionary of Regulatory Activities (MedDRA) nomenclature will be used to code 
diagnosis or symptoms from medical histories, adverse events (AEs), indications for prestudy 
and concomitant medications.  In addition, the Drug Dictionary Enhanced (DDE) preferred 
drug names from World Health Organization (WHO) Drug Dictionary will be used to classify 
all prestudy and concomitant medications by drug class and drug names.   


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
13 
 
5.1.1.2 
Demographics and Other Baseline Characteristics 
Disposition and exit status, demographics and baseline characteristics will be performed on the 
mITT population. 
5.1.1.2.1 Disposition and Exit Status 
Subject disposition and exit status will be summarized overall and by treatment group using 
frequency distributions at the primary efficacy endpoint of week 24 as well as at the end of the 
study. 
Reasons for early termination include AEs, lack of efficacy as determined by investigator, lost to 
follow-up, personal reasons, protocol violation, and other reasons. Subjects who discontinue 
prematurely will be listed along with the corresponding reason(s) for their early termination.  
5.1.1.2.2 Protocol Deviations 
Significant (major) protocol deviations will be summarized using standard text by treatment 
group, and data listing will be presented. 
5.1.1.2.3 Demographics  
Demographic data will include age, sex, race, and ethnicity. Age will be summarized with 
descriptive statistics by treatment group and overall (ie, all treatment groups combined). In 
addition, age will be classified into categories of < 35 and ≥ 35 years, and race will be classified 
as White and non-White. Age group, sex, race and ethnicity will be summarized with frequency 
distribution by treatment group and overall, respectively. 
5.1.1.2.4 Baseline Characteristics 
Body mass index (BMI) is defined as weight (kg) / height (m)2. Weight, height, and BMI will be 
summarized with descriptive statistics by treatment group and overall. 
Baseline TAHC (terminal hairs/cm2), 
 
 will be 
summarized by left circular areas of 1 
 
, and right circular areas of 1 
 
. In 
addition, TAHC will be summarized within the area of  
 
 
 
   
The summary will be presented with descriptive statistics by treatment group and overall.  
Distribution of subject’s score of modified Norwood-Hamilton Scale of male-pattern baldness at 
baseline, Fitzpatrick skin type, Hair Loss history, and the Hair Satisfaction Assessment scale 
(HSA) will be presented with frequency distributions by treatment group and overall, 
respectively. 
A subject listing with demographics and baseline characteristics will be presented. 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
14 
 
5.1.1.2.5 Medical History 
Medical and surgical history will be analyzed on the mITT population.  
Medical history, encompassing abnormalities and surgeries reported as occurring before the 
Screening Visit, will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), 
version 19.1 or newer. Unique subjects who report medical history events will be summarized by 
the primary system organ class (SOC) and preferred term (PT) (per MedDRA definition) for each 
treatment group and overall using frequency distributions.  
5.1.1.2.6 Prior and Concomitant Medications 
Prior and concomitant medications will be analyzed on the mITT population.   
Prior medications include all medications with a start date before the day 1 date, whether or not 
medication is continuing beyond the baseline visit.   
Concomitant medications encompass all non-study medications that the subject was taking prior 
to day 1 visit that are ongoing at the visit, in addition to all medications that have a start date on 
or after baseline (day 1) visit date.   
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version March 2016 or newer. Unique subjects who reported medications will be summarized by 
Anatomical Therapeutic Chemical (ATC) 4 class and PT in total and by treatment group in mITT 
population. No statistical comparisons will be performed. 
5.1.1.3 
Efficacy Analyses 
Efficacy analyses will be based on the mITT Population. Hypothesis testing will be 2-tailed with 
a significance level of 0.05, unless specified otherwise.  Treatment comparison will be made for 
Setipiprant versus Placebo. For all efficacy analyses, no adjustment of significance levels will be 
made for multiplicity of treatment comparisons.  
5.1.1.3.1 Collection and Derivation of Primary and Other Efficacy 
Measurements   
The coprimary efficacy variables will be based on the following 2 measures: TAHC within a 
1 cm2 circular area on the left side of the scalp and SSA. 
• The TAHC is a standardized objective quantification of each subject’s number of terminal 
hairs (hair width ≥ 30 µm) within a 1 cm2 target circular area on the left side located at the 
anterior leading edge of the vertex thinning area of the scalp using digital image analysis. 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
15 
 
• The SSA score is the subject’s assessment of change of hair growth, scored on a 7-point scale 
(−3 = greatly decreased, −2 = moderately decreased, −1 = slightly decreased, 0 = remained the 
same, +1 = slightly increased, +2 = moderately increased, and +3 = greatly increased). The 
analyses of the SSA from the blinded photograph assessments will be based on the actual 
change from the screening photographs (ie, if the postbaseline photograph is used as Photo A, 
the assessment score will be reversed for analyses). 
The coprimary efficacy endpoints based on the measurements of TAHC and SSA (blinded) are 
the following. 
• Change from baseline in TAHC within a 1 cm2 target circular area on the left side located at 
the anterior leading edge of the vertex thinning area of the scalp at Week 24 
• Subject Self-Assessment of change from baseline in hair growth as viewed on the subject’s 
paired (before and after presented in a blinded fashion) global photographs of the vertex 
target area at Week 24 and measured by the distribution of SSA scores  
Postbaseline evaluations of TAHC and SSA will be made at Week 
 24 and 32, with the 
primary analysis timepoint being Week 24.  For SSA, if the postbaseline photograph is used as 
Photo A, then the assessment score will be reversed for analyses. 
For each of the 2 coprimary measures (TAHC and SSA), missing data will be imputed up to 
Week 24 using last observation carried forward (LOCF) method.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
17 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
18 
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
    
5.1.1.3.2  Primary Efficacy Analyses 
For analyses of TAHC, the following set of hypotheses will be used to compare setipiprant 
tablets 1000 mg BID versus placebo BID: 
• Null hypothesis: There is no difference between setipiprant tablets 1000 mg BID and placebo 
BID in increasing TAHC (terminal hairs in a 1 cm2circular area) as measured by the change 
from baseline at Week 24 using digital image analysis. 
• Alternative hypothesis: There is a difference between setipiprant tablets 1000 mg BID and 
placebo BID in increasing TAHC (terminal hairs in a 1 cm2 circular area) as measured by the 
change from baseline at Week 24 using digital image analysis. 
For analyses of the SSA, the following set of hypotheses will be used to compare setipiprant 
tablets 1000 mg BID versus placebo BID: 
• Null hypothesis: There is no difference between setipiprant tablets 1000 mg BID and placebo 
BID in SSA (blinded) of hair growth from baseline at Week 24. 
• Alternative hypothesis: There is a difference between setipiprant tablets 1000 mg BID and 
placebo BID in SSA (blinded) of hair growth from baseline at Week 24. 
Change from baseline in TAHC at Week 24 and SSA of the change of hair growth from baseline 
at Week 24 will be analyzed using an analysis of covariance (ANCOVA) model with treatment as 
a fixed effect and age and baseline value as covariates (if applicable). The treatment difference 
for setipiprant tablets 1000 mg BID versus placebo BID will be constructed based on this 
ANCOVA model, along with the 2-sided p-value.  


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
19 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1.1.4 
Safety Analyses 
All safety analyses will be performed on the safety population.  All analyses will be based on 
observed cases without imputation. 
5.1.1.4.1 Study Treatment Exposure 
Subjects’ exposure to the study medication will be characterized by duration of treatment 
exposure.   
Duration of subject exposure to study treatment (days) will be calculated as the study treatment 
end date minus study treatment start date +1.  Duration of treatment exposure will be 
summarized with descriptive statistics by treatment group. 
5.1.1.4.2 Adverse Events 
An AE is defined as any untoward medical occurrence in a subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. Adverse events are collected both for the screening/baseline period pretreatment 
(which are referred to as pretreatment AEs) and for the follow-up period after treatment is 
initiated (which are referred to as postbaseline AEs). Adverse events will be summarized using 
the concept of treatment-emergent adverse events (TEAEs). TEAE is a postbaseline AE where:  
a) there is no pretreatment AE of the same MedDRA primary system organ class (SOC) and 
preferred term (PT); or  
b) the maximum severity during the postbaseline period is greater than the maximal severity 
of any pretreatment AE of the same MedDRA primary SOC and preferred term during the 
screening/baseline period;  or 
c) the AE reports as a serious AE (SAE) during the postbaseline period  
Analysis of the incidence of TEAEs will be performed over the entire study period, and the 
incidence of TEAEs will be presented and summarized as follows: 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
21 
 
(1) Overall AE, treatment related TEAE, serious AE, deaths, AEs leading to discontinuation and 
Non-scalp hair growth. 
(2) TEAEs by primary SOC in alphabetical order, PT and severity (maximum severity). The 
maximum severity of a TEAE experienced by a subject is determined by the greatest severity 
recorded on the eCRFs for the subject’s given TEAE.     
(3) Common (>=2%) TEAEs by Preferred Term 
(4) Treatment related TEAEs by primary SOC in alphabetical order, and preferred term.  
(5) Treatment-emergent serious AEs (SAE) by SOC in alphabetical order, and preferred term.  
(6) TEAEs leading to treatment discontinuation by SOC in alphabetical order, and preferred term  
(7) Treatment-emergent SAE with fatal outcome by primary SOC in alphabetical order, and 
preferred term. Subject listings will be generated for all AEs, SAE, Deaths, and AEs leading 
to study discontinuation.   
Participant listings will be provided for all AEs, SAEs, AEs leading to study treatment 
discontinuation, and death (if occurred). 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
22 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
    
 
 
  
 
 
 
 
  
 
 
 
   


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
23 
 
5.1.1.4.6 Other Analyses 
5.1.1.4.6.1 Nonscalp Hair Growth 
Starting at Week 8, subjects will be queried at each visit whether they have noticed any hair 
growth in nonscalp areas (yes/no) and this response will be captured in the eCRF. If judged by 
the investigator as clinically significant, nonscalp hair growth may be reported as an AE. 
The nonscalp hair growth will be summarized separately with a frequency distribution by 
treatment group.    
5.1.1.5 
Subgroup Analyses 
Subgroup analyses are not planned but might be performed as Ad hoc analyses after database 
lock. 
5.1.1.6 
Interim Analyses 
Not applicable. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Allergan C
Setipiprant
 
 
C
5.2
5.2.1 C
Not appli
5.2.2 C
Not appli
6. 
D
 
S
6.1
6.1.1 A
• Study
after 
• Treat
the st
6.1.2 M
If the inv
to the las
Confidential 
t Tablets 
Changes in
Changes in
icable. 
Changes to
icable. 
Data Hand
Study Trea
Analysis D
y days will b
baseline dat
tment period
tudy treatme
Missing/In
vestigator is u
st treatment a
n the Cond
n the Cond
o Analyses
dling and A
atment Co
ays 
be calculated
te; otherwise
d is defined a
ent end. 
complete 
unable to pr
application, 
duct of the
duct of the
s Prior to D
Analysis C
nventions
d as visit date
e it will be ca
as days betw
Treatmen
ovide the tre
or early exit
24 
e Study or
e Study 
Database L
Convention
s 
e – baseline 
alculated as 
ween the date
t End Dat
eatment end 
t, or week 24
r Planned A
Lock 
ns 
date (day 1)
visit date -b
e of study tre
te 
date, treatm
4 visit, which
Analyses 
) + 1 if visit 
aseline date 
eatment start
ment end date
hever is the 
SAP 1922-20
date is on or
(day 1). 
t and the dat
e will be imp
first. 
01-002 
r 
e of 
puted 


Allergan C
Setipiprant
 
 
M
6.3
Partial A
Partial A
1) If day
2) If bot
3) If imp
pre-tr
Imputed 
Partial A
1) If day
2) If bot
The date 
The date 
follows: 
1) If day
Confidential 
t Tablets 
Missing Da
E dates will 
AE onset date
y is missing 
th day and m
puted onset 
reatment, the
partial AE o
AE stop date w
y is missing 
th day and m
of first incre
of first incre
  
y is missing 
ate Inform
be imputed 
e will be imp
but month is
month are mi
date is befor
en impute th
onset date wi
will be impu
but month is
month are mi
ease in sever
ease in sever
but month is
mation for 
using the be
puted as follo
s not, impute
issing, imput
re the first tr
he onset date
ill only be us
uted as follow
s not, impute
issing, imput
rity to mode
rity (to mode
s not, impute
25 
Adverse E
elow method
ows:   
e the date as
te the date a
reatment, yet
e as the first t
sed to determ
ws:   
e the date as
te the date a
rate, if a par
erate or seve
e the date as
Events 
ds. 
s the first day
s 01 Jan;  
t the corresp
treatment da
mine the AE
s the last day
s 31 Dec.  
rtial date, wi
ere), if a part
s the 15th of 
y of the mon
ponding AE w
ate.   
E onset cycle
y of the mont
ill be impute
tial date, wil
f the month;  
SAP 1922-20
nth;  
was not obse
e.   
th;  
ed as follows
ll be imputed
01-002 
erved 
s:   
d as 


Allergan C
Setipiprant
 
2) If bot
3) If imp
durin
4) If imp
impu
Imputed 
partial da
 
M
6.4
For prior
missing) 
both inco
imputed)
stop date
concomit
6.4.1 M
The follo
or concom
• M
1) If the
treatm
missi
2) If the
Dece
3) If the
Janua
• M
If only th
will be re
• M
1) If the
first d
the m
Confidential 
t Tablets 
th day and m
puted partial
ng treatment 
puted partial
ute the partia
partial AE d
ates will be l
Missing/In
r or concomi
start dates a
omplete for a
) and the imp
e. Imputed pa
tant medicat
Missing/Inco
owing rules w
mitant medi
Missing mon
e year of the 
ment, the mo
ing fields;   
e year of the 
mber 31 wil
e year of the 
ary 1 will be
Missing mon
he month is m
eplaced acco
Missing day 
e month and 
dose of study
missing day; 
month are mi
l date is befo
study period
l date is befo
l date as the 
dates will on
listed “as is”
complete 
itant medicat
and/or stop d
a patient, the
puted start da
artial medica
tion.  All par
omplete Star
will be appli
cation start d
nth and day
incomplete 
onth and day
incomplete 
ll be assigne
incomplete 
e assigned to
nth only 
missing, the 
ording to the
only 
year of the i
y treatment, 
 
issing, imput
ore the first t
d, then impu
ore the onset
later of thes
nly be used to
” in the data 
Date for P
tions, includ
dates will be 
e start date w
ate is after th
ation start/st
rtial dates wi
rt Date  
ied to impute
date. 
y 
start date is 
y of the first 
start date is 
d to the miss
start date is 
 the missing
day will be 
 above proce
incomplete s
the day of th
26 
te the date a
treatment, an
ute the date a
t date or the 
se two dates.
o determine 
listings.   
Prior and C
ding rescue m
imputed. W
will be imput
he stop date,
op dates wil
ill be listed “
e the missing
the same as 
dose of stud
before the y
sing fields; 
after the yea
g fields. 
treated as m
edure. 
start date are
he first dose
s 15 June;  
nd the corres
as the first tre
date of first 
.   
treatment-em
Concomit
medications,
When the start
ted first.  If t
, the start da
ll only be use
“as is” in the
g numeric fi
the year of t
dy treatment 
year of the fir
ar of the first
missing and b
e the same as
e of study tre
sponding AE
eatment date
increase in 
mergent AE 
tant Medic
 incomplete 
t date and th
the stop date
ate will be im
ed to determ
e data listing
ields for an i
the first dose
will be assig
rst dose of s
t dose of stu
both the mon
s the month 
eatment will 
SAP 1922-20
E was observ
e;  
severity, the
(TEAE).  A
cations 
(ie, partly 
he stop date a
e is complete
mputed using
mine prior or 
gs.  
ncomplete p
e of study 
gned to the 
study treatme
udy treatmen
nth and the d
and year of 
be assigned
01-002 
ved 
en 
All 
are 
e (or 
g the 
prior 
ent, 
nt, 
day 
the 
d to 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
27 
 
2) If either the year of the incomplete start date is before the year of the date of the first dose of 
study treatment or if both years are the same but the month of the incomplete start date is 
before the month of the date of the first dose of study treatment, the last day of the month 
will be assigned to the missing day;  
3) If either the year of the incomplete start date is after the year of the date of the first dose of 
study treatment or if both years are the same but the month of the incomplete start date is 
after the month of the date of the first dose of study treatment, the first day of the month will 
be assigned to the missing day. 
6.4.2 Missing/Incomplete End Date 
The following rules will be applied to impute the missing numeric fields for an incomplete prior 
or concomitant medication stop date. If the date of the last dose of study treatment is missing, 
impute it as the method in the Section 6.1.2. If the imputed stop date is before the start date 
(imputed or nonimputed start date), the imputed stop date will be equal to the start date. 
• Missing month and day 
1) If the year of the incomplete stop date is the same as the year of the last dose of study 
treatment, the month and day of the last dose of study treatment will be assigned to the 
missing fields;   
2) If the year of the incomplete stop date is before the year of the last dose of study treatment, 
December 31 will be assigned to the missing fields;  
3) If the year of the incomplete stop date is after the year of the last dose of study treatment, 
January 1 will be assigned to the missing fields. 
• Missing month only  
If only the month is missing, the day will be treated as missing and both the month and the day 
will be replaced according to the above procedure.    
• Missing day only  
1) If the month and year of the incomplete stop date are the same as the month and year of the 
last dose of study treatment, the day of the last dose of study treatment will be assigned to the 
missing day;  
2) If either the year of the incomplete stop date is before the year of the date of the last dose of 
study treatment or if both years are the same but the month of the incomplete stop date is 
before the month of the date of the last dose of study treatment, the last day of the month will 
be assigned to the missing day;  


Allergan C
Setipiprant
 
3) If eith
study
after 
be as
 
Im
6.5
Missing d
Week 24 
in a parti
carried fo
unschedu
missing d
be carried
without d
 
 
Im
6.7
In genera
that may 
imputed 
listing sp
7. 
D
Some fie
privacy w
8. 
R
Cotsareli
Philadelp
Harcha G
efficacy a
Confidential 
t Tablets 
her the year 
y treatment o
the month o
signed to the
mputation
data of all TA
using last o
icular visit w
orward and u
uled visit.  Im
data occur at
d forward fo
data imputat
mputed V
al, listings w
be used in e
values will b
pecification d
Data Colle
elds collected
was signed) b
References
is G, Zheng Y
phia: Univer
G, Martinez B
and safety o
of the incom
or if both yea
of the date of
e missing da
n of Prima
AHC endpoi
bservation c
window, the l
used for anal
mputation w
t scheduled v
or imputation
ion.  
Value Listin
will present th
endpoint der
be flagged. A
document. 
cted but N
d on the eCR
but will be l
s 
Y,Hsieh J.  E
rsity of Penn
B, Tsai TF, e
f different d
mplete stop d
ars are the sa
f the last dos
ay. 
ary Efficac
ints and SSA
carried forwa
latest non-m
lysis for that
will be applie
visit(s) imm
n.  Analyses 
ng Conven
he actual par
ivation. In in
Actual rules 
Not Analyz
RF may be n
isted.  
Evaluation o
sylvania; 20
et al. A rand
doses of duta
28 
date is after t
ame but the m
se of study tr
cy Measur
A (blinded an
ard (LOCF) 
missing obser
t particular w
d to postbas
ediately foll
of Week 32 
ntions 
rtial or missi
nstances whe
will be fully
zed 
ot analyzed 
of DP-2 anta
015a. 
domized, acti
asteride versu
the year of th
month of the
reatment, the
rements (T
nd unblinded
as follows: w
rvation prior 
window, whe
eline visits u
lowing basel
data will be
ing values ra
ere imputed
y defined in t
(eg, photogr
agonists in p
ive- and plac
us placebo a
he date of th
e incomplete
e first day of
TAHC and
d) will be im
when there i
to that visit 
ether from a
up to Week 2
line, the base
e based on ob
ather than th
values will 
the table, fig
raphy consen
promotion of
cebo-contro
and finasterid
SAP 1922-20
he last dose o
e stop date is
f the month w
d SSA) 
mputed up to
is no observa
window wil
a scheduled o
24 only. If 
eline value w
bserved case
he imputed v
be presented
gure, and dat
nt, and subje
f hair growth
lled study of
de in the 
01-002 
of 
s 
will 
 
ation 
ll be 
or 
will 
es 
alues 
d, 
ta 
ect 
h. 
f the 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
29 
 
treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-
498.  
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in 
the treatment of male pattern hair loss: results of a randomized placebo-controlled study of 
dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.  
9. 
Amendment 1 
The following amendments were made from the originally approved SAP/TFL shells. 
• New analyses were specified in Sections 5.1.1.3.3, 5.1.1.4.2 and 5.1.1.4.3 with the 
following new tables and listings added  
 
 
 
  
o Table 14.3-2.4 Number (%) of Participants with Common (>=2%) Treatment-
Emergent Adverse Events by Preferred Term 
o Table 14.3-4.4 Potential Hy’s Law Criteria: Number of Participants Meeting 
Criteria 
o Figure 14.3-4.4-1 The maximum postbaseline TBL elevation vs the maximum 
postbaseline ALT elevation 
o Figure 14.3-4.4-2 The maximum postbaseline TBL elevation vs the maximum 
postbaseline AST elevation 
o Listing 14.3-4.5 Laboratory Parameters: Potential Hy’s Law Criteria Findings  
o Table 14.3-4.6 Shift from Baseline to End of Treatment in Hematology and 
Chemistry Parameters 
 
 
 
 
 
 
• Some TFLs were re-numbered in the shells due to deletion and addition of tables/listings 
10. 
Amendment 2 
The following updates were made relative to Amendment 1 of the SAP: 


Allergan Confidential 
SAP 1922-201-002 
Setipiprant Tablets 
30 
 
• Section 5.1.1.1.4: Text was added to clarify that the baseline values used for 
macrophotography (TAHC, 
) may include photos taken after the first 
dose of study drug when a reshoot was required to obtain evaluable baseline 
measurements. 
 
 
 
  
• 
Section 6.5: Clarification was made to indicate that the LOCF missing data imputation 
will be done for all TAHC endpoints and SSA (blinded and unblinded). In addition, more 
details of how the LOCF algorithm will be done are provided.   
 


ALLERGAN 
 
 
 
 
 
 
 
 
 
Date (DD/MMM/YYYY)/Time (PT) 
Signed by: 
Justification 
  
 
 
            
 
           
 
            
 
           
 
            
 
           
 
     
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
           
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
            
 
        
 
 
Analysis Plan for 1922-201-002 Amendment 2